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To Maria, Jonatan, David and Junis 
“The seemingly impossible is possible” 
Hans Rosling 
“It is not the path which is the difficulty; 
 rather, it is the difficulty which is the path” 
Søren Kirkegaard 
“But as long as a man has the strength to dream 
He can redeem his soul and fly”  
Elvis Presley 
ABSTRACT 
Background: Many endoscopists have since the beginning of endoscopic retrograde 
cholangiopancreatography (ERCP) commented on the variation in the macroscopic appearance of 
the papilla of Vater. How the macroscopic appearance of the papilla influences the cannulation 
efforts during ERCP has been discussed but not previously investigated in-depth. The endoscopic 
appearance can also be distorted by neoplastic lesions that can develop into cancer if not treated in 
time. Endoscopic papillectomy has evolved as a treatment option to cure these lesions if detected at 
an early stage. This thesis focuses on the influence of the endoscopic appearance on transpapillary 
cannulation, also how to clinically manage early neoplastic lesions situated in the papilla of Vater. 
Objectives: I), To introduce a new inter- and intraobserver validated classification of the 
endoscopic appearance of the papilla of Vater. II), Apply the classification to investigate if the 
endoscopic appearance influences transpapillary cannulation during ERCP. III), Evaluate the 
minimally invasive method of endoscopic papillectomy in the treatment of early neoplastic lesions 
in the papilla of Vater, including evaluating the significance of KRAS analysis on the resected 
specimen. IV), To investigate what symptoms and preinterventional findings that could be of value 
for clinical decision-making when choosing the best method to resect ampullary neoplastic lesions 
when an invasive malignancy is not clear. 
Methods: I) Constructing a web-based survey where 18 endoscopists categorized photos of 50 
different papillae from the suggested classification. II). A Nordic multi-center study, measuring bile 
duct cannulation in 1401 patients after the papillae have been categorized into one of the distinct 
papilla types from the proposed classification. Determination of the frequency of difficult 
cannulation among the papilla types. III). A case series including 36 patients treated with 
endoscopic papillectomy, evaluating the clinical outcome and safety. Also, determining the status in 
the resected specimen of mutated KRAS to evaluate if that could predict the clinical prognosis. IV) 
A descriptive analysis of all patients treated with endoscopic papillectomy and/or surgical resection 
for verified or suspected ampullary neoplasia from 2006 to June 2018, where no invasive lesion was 
seen at cross-sectional imaging. Analyzing the symptoms, the histopathological results, and other 
investigational findings, comparing these with the final diagnosis after resection. 
Results: The classification consisting of four distinct types of papillae showed a substantial inter- 
(κ=0.62) and intraobserver (κ=0.66) agreement among beginners as well as experienced 
endoscopists and was therefore possible to use in study II. The second study showed that bile duct 
cannulation was significantly more often difficult in small papilla, Type 2 (52%, 95% CI 45-59%) 
and protruding or pendulous papilla, Type 3 (48%, 95% CI 42-53%) compared to regular, Type 1 
papilla (36%, 95% CI 33-40%). Failure to cannulate were more frequent if an inexperienced 
endoscopist started cannulation attempts. In study III 50% of the patients were cured from 
adenomatous neoplasia with endoscopic papillectomy. A small number of patients had mild to 
moderate complications. The results from KRAS analysis were hard to interpret. The 
preinterventional diagnosis changed in many patients after the endoscopic resection, raising 
questions that will be addressed in study IV. In study IV, if a histological diagnosis of malignancy 
could not be made before surgical resection, there was a high frequency of patients with benign or 
early neoplastic lesions treated with major pancreatic surgery. If endoscopic forceps biopsies show 
adenoma, endoscopic papillectomy has a curative potential in 59% of the patients. 
Conclusions: 1. The macroscopic appearance of the papilla of Vater influences bile duct 
cannulation during ERCP, both among experts and beginner endoscopists: 2. Endoscopic 
papillectomy is a reasonably safe procedure with the potential to cure early neoplastic lesions in the 
papilla of Vater, and if not curative, offer a comprehensive tissue diagnosis that can guide clinical 
management. 3. Before deciding on surgical resection of a suspected neoplastic ampullary lesion, 
efforts must be made to get a histological confirmation of malignancy. When biopsies show 
adenoma, endoscopic papillectomy should be considered to cure the patient or at any rate get a 
confirmation of malignant disease. 
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1 BACKGROUND 
1.1 HISTORY 
Abraham Vater (1684-1751) (Flati and Andrén-Sandberg 2002) presented in his anatomical 
dissertation at the University of Wittenberg (1720), a dilatation (diverticula) at the junction 
of the bile duct and the pancreatic duct before their joint opening into the duodenum, now 
days referred to as the Ampulla of Vater (Vater 1720). The name ampulla referring to an 
ancient Roman glass or earthenware flask with two handles and a globular body made to 
hold precious fluids (Gaspar and Shami 2015), Figure 1. Similarly, the ampulla of Vater 
“holds” two of the body’s most precious fluids, bile, and pancreatic juice.
Figure 1. “Ampulla” Coptic. Pilgrim Flask, 5th-7th century C.E. Terracotta 
From Brooklyn Museum online collection. "Pilgrim Flask" is licensed under CC BY 3.0 
Abraham Vater was not the first to describe the biliopancreatic ampulla or the junction of 
the bile duct and the main pancreatic duct (Wood 1979; Stern 1986). Already Vesalius, in 
1543, described that the bile duct drains into the duodenum (Hand 1963) and later Wirsung, 
in 1642, when he described the main pancreatic duct noted that the orifice of the ducts 
emptied into the duodenum at the papilla. Santorini should probably have the honors for 
correctly describing the joint distal ends of the pancreatobiliary ducts. Mirilas et al. (2005) 
mean that what Abraham Vater described was a peri-vaterian diverticulum and not the 
anatomical ductal dilatation that now bears his name,. 
Abraham Vater died in 1751 after five days of jaundice (Lerch and Domschke 2000) but his 
name is forever ascribed to this anatomical structure. The name of Vater has also been 
given to the mucosal protrusion, bulging out from the medial duodenal wall referred to as 
the papilla of Vater. This nipple-like protrusion holds the orifice of the joint 
pancreatobiliary duct as it opens into the intestine, and was mentioned already by Vesalius 
and described in more detail by Samuel Collins in 1685 (Stern 1986), Figure 2.  
1.2 EPONYMS AND TERMINOLOGY 
The eponym’s papilla of Vater and ampulla of Vater should possibly be avoided to prevent 
mistakes and mix-ups between these two different, but closely related, anatomic structures 
(Mirilas et al. 2005). Naming the ampulla and the papilla with the same eponym can be 
confusing. It is suggested that the use of these eponyms should be abandoned and instead 
use the terms, major duodenal papilla and biliopancreatic ampulla (Mirilas et al. 2005). 
Nevertheless, the terms Papilla of Vater and Ampulla of Vater are widely used and are seen 
in many recent publications (Imamura et al 2019; Kim et al. 2019) 
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Figure 2. The Pancreas and Duodenum with the Papilla of Vater (highlighted)
Henry Gray (1821–1865), Anatomy of the Human Body, 1918 (copyright expired). 
Two other terms that also need some clarification are, the ampullary region, and the 
periampullary region. When discussing about tumors in the ampullary and periampullary 
regions, the terms are sometimes used in an unclear manner.  
Periampullary carcinomas are often defined as all malignant tumors arising within 2 cm of 
the major duodenal papilla (Sarmiento et al. 2001), or all tumors that can be resected with a 
standard pancreatoduodenectomy (Whipple´s procedure) (He et al. 2014), Figure 3.The 
term “periampullary tumors” incorporate four different malignancies in the proximity of the 
ampulla: pancreatic cancer in the head of the pancreas, distal bile duct cancer, ampullary 
cancer, and duodenal cancer.  
Figure 3. The periampullary region, with the ampullary region encircled. The ampullary region 
includes the ampulla, the papillary prominence, the sphincteric apparatus and the duodenal 
mucosal surface of the papilla. 
Adopted from Davee, T. et al. (2012). Precut sphincterotomy for selective biliary duct cannulation during 
endoscopic retrograde cholangiopancreatography. Annals of Gastroenterology 25(4), 291-302. 
https://www.ncbi.nlm.nih.gov/pubmed/24714256  
Licensed under CC-BY-NC SA 3.0 
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The ampullary region is the central part of the periampullary region and has four distinct 
parts centered around the opening of the biliopancreatic ductal systems into the intestine, 
Figure 3. First, the ampullary region includes the distal parts of the common bile duct and 
the pancreatic duct as they pass through the duodenal wall before opening into the duodenal 
lumen. The ducts either merge into a dilated common channel, the ampulla of Vater with a 
single ductal opening, or continue as two separate ducts thru the papilla. Secondly, there is 
the papilla of Vater, which is the duodenal protuberance in the second part of the 
duodenum, the nipple-like structure surrounding the ducts as they enter the intestine. The 
third part of the ampullary region is the duodenal intestinal mucosa (ampullary duodenum) 
covering the outside of the papilla. Finally, the complex of smooth muscles (sphincter of 
Oddi) together with the accessory pancreatobiliary ducts and the mucous glands around the 
ampulla also are part of the ampullary region (Dhall et al. 2015).  
In some reports are the ampullary adenocarcinomas that originates from the duodenal 
surface, on the outside of the papilla (ampullary duodenum), called periampullary 
carcinomas. The use of the term periampullary tumors are therefore not clear and can be a 
source for confusion. 
1.3 ANATOMY OF THE AMPULLARY REGION 
1.3.1 The papilla of Vater 
The papilla of Vater, or major duodenal papilla, is in most humans (82 %), located on the 
posteromedial wall of the second part of the duodenum, about 10.5 cm (range 7-13 cm) 
from the pylorus (Lindner et al. 1976; Flati et al. 1994), Figure 4. It can be found closer to 
the pylorus on rare occasions and even in the third part of the duodenum (Dowdy et al. 
1962). Lindner et al. (1976) reported that intraoperative cholangiograms, in as much as 
13% of the patients, revealed that the common bile duct ended distal to or at the lower 
angle of the duodenum.  
Figure 4. The anatomical landmarks of the Papilla of Vater. 
The shape of the papilla is usually cylindric-conic (78%) or hemispheric (14%) with a 
single ductal opening (94%) holding the orifice of the joint pancreatobiliary ductal systems 
(Flati et al. 1994; Horiguchi and Kamisawa 2010). Anatomical studies have described it as 
having a width of 5 mm (range 3-8 mm) and a protrusion of 7.7 mm (range 0-20mm) 
(Dowdy et al. 1962; Flati et al. 1994; Avisse et al. 2000; Skalicky 2011). The papilla, is in 
most patients (86%), partially or entirely, covered by a supra-papillary mucosal fold (hood) 
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and is in 76% of people associated with one or several caudally extending longitudinal 
folds (frenulum) of variable length (Avisse et al. 2000; Kim et al. 2008). 
Endoscopists can use the frenulum, inferior of the papilla, as a guide when trying to locate 
the papilla during endoscopic examinations of the duodenum.  
1.3.2 Ductal anatomy 
Inside the papilla, there is considerable variability in the anatomy of the pancreatobiliary 
ductal system (Hand 1963), Figure 5. The junction of the bile duct and the main pancreatic 
duct can be classified into four types depending on how and if the ducts merge and in what 
way they merge inside the duodenal wall (Dowdy et al. 1962). The most frequent is the Y 
type (60%), with a common channel of more than 1.5 mm and a classic ampulla. The Y-
type can be divided into a short (type a, 1.5-10 mm) or a long (type b, >10mm) type, 
depending on the length of the merged channel. In the U type (22%), the ducts are in 
parallel, with only an interductal septum separating the ducts all the way to the orifice. The 
ducts have separate openings on the papilla but in the same papilla. There are no muscle 
fibers separating the ducts in the U-type. Neither does the V type (14%), have the classic 
ampulla, instead, it has a short common channel, less than 1.5 mm long. The last type is the 
uncommon, II type with separate orifices in two separate papillae with separate sphincteric 
muscles (Dimagno et al. 1982; Wilasrusmee and Pongchairerks 1999, Kim et al. 2008).  
If the common channel is even longer, >15 mm, or merge outside the duodenal wall, it is 
considered to be a congenital anomaly, pancreaticobiliary maljunction (Misra and Dwivedi 
1990; Kamisawa et al. 2012, 2014) . Pancreatobiliary maljunction is a risk factor for the 
development of bile duct carcinoma (Kamisawa et al. 2017; Hyvärinen et al. 2019), 
gallbladder carcinoma (Kamisawa et al. 2017b), or acute and chronic pancreatitis 
(Kamisawa et al. 2002; Löhr et al. 2012).  
1.3.3 The Sphincter of Oddi 
Underneath the mucosal surface, there is an intricate neuromuscular system with several 
sphincteric muscles that encircle the distal ends of the pancreatic and biliary ducts and the 
distal end of the common duct in the ampulla. This system of smooth muscular bundles is 
called the sphincter of Oddi (1887). The small sphincteric smooth muscles are regulated by 
several neurohormonal mediators, and they act separately from the musculature of the 
duodenal wall. The sphincteric apparatus acts to regulate the outflow of bile and pancreatic 
juice but also to obstruct duodenal content from entering the ducts (Staritz 1988; Kher and 
Guelrud 2004). 
Dietary fat in the duodenal lumen, as well as acidic content, causes the sphincteric 
mechanism to relax (Kalloo and Pasricha 1995; Rosenblatt et al. 2001) opening up for the 
outflow of bile and pancreatic juice. These physiological functions of the sphincteric 
apparatus might ease cannulation during ERCP (Barrie et al. 2006; Fang et al. 2018). 
Several pharmaceutical substances have also been tested for both relaxation and contraction 
of the sphincteric mechanism and their potential effect on bile duct cannulation during 
ERCP (Thompson 2001; Woods and Saccone 2007).  
1.4 HISTOLOGY OF THE AMPULLARY REGION 
The ampullary region is a meeting point for several histologically different structures in a 
small area. The distal ends of the main pancreatic and common bile ducts; the intestinal 
mucosa on the duodenal outer surface of the ampulla; the ductules in the ampullary wall 
and the transitional zone of the papilla of Vater (Pant et al. 2018).  
The outer surface of the major duodenal papilla, ampullary duodenum, is covered with 
intestinal simple columnar epithelium of small intestinal type, consisting of enterocytes, 
and with a higher frequency of interspersed goblet cells compared to further down in the 
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small intestine. On the papilla of Vater, the area of transition between the intestinal mucosa 
and the ductal epithelium, there is a mixture of foveolar-like cells and increased amounts of 
goblet cells. Inside the pancreatobiliary ducts or ampulla, the mucosa forms prominent 
papillary folds with a fibrovascular core, meant to minimize the reflux of duodenal content 
into the ductal system (de Sanctis and Tagliaferri 1968). In situations where there is no real 
ampulla, these extensive papillary folds instead fill out the distal part of the separate ducts. 
The extensive folds inside the ampullary lumen may play a part in difficulties during bile 
duct cannulation (Paulsen et al. 2002). The more proximal bile duct or pancreatic ducts are 
lined by cylindrical, monostratified, ductal epithelium with occasional goblet cells, but no 
absorptive-type cells (Frierson 1989).  
Figure 5. The different variants of ductal anatomy in the ampullary region. (A); Y-Type with 
developed ampulla. (B) V-Type, with very short (<1,5mm) common channel, (C) Y-Type with long 
common channel (> 10 mm), (D) U-Type, with a septum between the ducts all the way to the orifice. 
(E) II-Type, with two separate orifices and sometimes separate papillae. (F) Papilla with separate 
orifices.
From: Dimagno, E. et al., (1982) “Relationships between pancreaticobiliary ductal anatomy and pancreatic 
ductal and parenchymal histology”, Cancer 49(2), 361-368. 
Reprinted with permission from John Wiley and Sons. 
https://doi.org/10.1002/1097-0142(19820115)49:2%3C361::AID-CNCR2820490225%3E3.0.CO;2-O
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1.5 ENDOSCOPIC APPEARANCE OF THE PAPILLA OF VATER 
Besides the anatomical characteristics of the major duodenal papilla, there are many 
variations in the endoscopic appearance, as seen at the time of endoscopic examination, 
Figure 6. The papilla may be large or small, swollen by diseases or hidden under the supra-
papillary mucosal folds, and the amount of protrusion may also differ considerably (Silvis 
et al. 1983, Lee et al. 2014b). There has since the beginning of endoscopic bile duct 
cannulation been several authorities mentioning that the appearance of the papilla 
contributes to difficult or failed cannulation (Bourke et al. 2009; Swan et al. 2011; Bakman 
and Freeman 2013; Pan et al. 2015; Testoni et al. 2016). To date, there is no validated 
classification of the endoscopic appearance of the major duodenal papilla.  
Horiuchi et al. (2007) presented a classification of the endoscopic appearance of the papilla, 
based on the amount of protrusion on the oral side of the papilla. In their classification there 
was no interobserver agreement validation made to see if different endoscopists had similar 
opinions of the types of papillae that they proposed. The classification included three types 
of papillae. Small type, with no oral protrusion, large type, with oral protrusion and the 
swollen type, with marked oral protrusion. These three different papilla types were applied 
to guide the endoscopists in selecting pre-cutting technique after they had failed with 
routine cannulation. In the classification, suggested by Horiuchi et al., there was no 
distinction between the different appearances of the papilla if there were no oral protrusion; 
instead, all papillae without protrusion were called small. Lee et al. (2011) expanded the 
classification proposed by Horiuchi et al. (2007), to include a “distorted type” ascribed to a 
papilla with unclassifiable characteristics. They measured successful cannulation between 
the different papilla types when using pre-cut fistulotomy technique after failed primary 
cannulation. They could not draw any conclusions about the different appearances of the 
papilla and the cannulation frequency. 
1.5.1 Cannulation and the appearance of the papilla of Vater 
Swan et al. (2011) proposed a list of risk factors that could cause failed cannulation, and 
among those factors were “a long and mobile intraduodenal part of the bile duct” or a 
“small papilla” mentioned. When discussing cannulation difficulties and the use of 
auxiliary techniques, it is suggested that endoscopists should use transpancreatic biliary 
sphincterotomy as the preferred pre-cut technique when having difficulties cannulating a 
small papilla (Katsinelos et al. 2012; Testoni et al. 2016), and the opposite approach, when 
cannulating a protuberant papilla, using either needle knife papillotomy or fistulotomy 
techniques instead (Katsinelos et al. 2015).  
Another technical aspect mentioned when trying to cannulate a “small” papilla is to use a 
technique with the guidewire protruding 2-3 mm out of the sphincterotome (Reddy et al. 
2017) to be more delicate when trying to find the correct duct. In a study about cannulation 
and ERCP-training, Pan et al (2015) found that an “abnormal papilla” was more difficult 
for a trainee to cannulate. The definition of an “abnormal papilla” was a “swollen, tiny, or 
hook-nose-shaped papilla”. The position of the papilla inside a diverticulum or “not in the 
second part of the duodenum” was also considered abnormal. 
None of the above examples have made any definition of the variation in appearance 
between the different types of papillae, and there has not been any quantification to what 
extent the difficulties during cannulation of a certain type of papilla exists. 
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Figure 6. Examples of the various endoscopic appearances of the papilla of Vater.
1.5.2 Diseases affecting the appearance of the papilla of Vater 
Already Leese et al (1986) described the difficulties in determining if the papilla was 
affected by neoplastic disease or inflammatory disease based only on the tumor-like 
endoscopic appearance of the papilla. Patients could have lesions that are inseparable on 
endoscopic inspection from those with malignancy, still, in 23 % of patients they turned out 
not to be malignant. Chang et al (1990) continued that discussion and noted that the 
presence of ulceration in a tumor-suspected lesion was more often a sign of underlying 
malignancy. Patients that proved to have a benign disease, even if the papilla had a 
malignant appearance, often had choledochal stones as the underlying explanation. 
Yamaguchi et al. (1990) described different endoscopic appearances of the papilla in 
patients with adenomas or carcinomas in the ampullary region. The papilla could be 
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protruding with intramural swelling caused by an underlying tumor, protruding with a 
visible tumor on the papilla surface, or having an ulcerating process. They reported that the 
ulcerating and the intramurally protruding appearances were in most patients malignant. 
The “exposed protruding” type could be either benign or malignant, and that the visual 
impression was of little use when faced with that type of endoscopic appearance.  
Lee et al. (2014a) noted that the endoscopic appearance and forceps biopsies have equal 
sensitivity at determining if a lesion is benign or malignant. In the work by DeOliveria et al 
(2006) they concluded that the endoscopic appearance during duodenoscopy had a higher 
sensitivity (86%) and accuracy (83%) to correctly diagnose a neoplastic lesion as 
malignant, compared to endoscopic biopsies, sensitivity (65%) and accuracy (67%). It is an 
interesting result and must be repeated in a more extensive study to draw any confident 
conclusions and the visual impression has to be validated among multiple observers to be 
useful. 
Kim et al (2008) reported that the bulging of the papilla, seen on MRI, but without a visible 
mucosal lesion could be caused by an ampullary tumor, impacted choledochal stones, 
secondary to a ductal mucin-producing tumor, or secondary to either cholangitis or 
pancreatitis.  
Skalicky (2011) measured several papillae before and after cholecystectomy using EUS and 
noticed that the papilla increased in size during the first months after the operation. This 
effect was transient, and the size of the papilla, on repeated measures, went back to the 
preoperative size again after six months. 
There are reports saying that a swollen papilla might also indicate that the patient has an 
autoimmune or sclerosing pancreatitis (Unno et al 2002). The swelling of the papilla 
attributed to autoimmune pancreatitis has been described as a severe swelling of the papilla 
itself and not of the supra papillary protrusion or the duodenal surroundings. This kind of 
swelling of the papilla corresponds to the swelling of the intraduodenal part of the 
biliopancreatic ducts (Kubota et al 2007). Combining the finding of a swollen papilla 
during endoscopic examination and biopsies of the papilla showing IgG4 positive plasma 
cells is, a clear sign of autoimmune pancreatitis (Kubota et al. 2007; Shimosegawa et al. 
2011). Kubota et al. (2008) also report that in patients with primary sclerosing cholangitis, 
there was rarely a swelling of the papilla. Patients with primary sclerosing cholangitis had 
more often a small or retracted papilla instead, and this could help to differentiate between 
sclerosing cholangitis secondary to autoimmune pancreatitis and primary sclerosing 
cholangitis. Others have also noted that retraction of the papilla are a frequent finding in 
patients with extrahepatic primary sclerosing cholangitis (Parlak et al. 2007, 2015). How 
these kinds of endoscopic appearances of the papilla influences bile duct cannulation during 
ERCP, has not been studied. 
1.6 ADENOMATOUS NEOPLASIA OF THE AMPULLARY REGION 
1.6.1 Premalignant lesions in the ampullary region 
Most ampullary adenocarcinomas originate from pre-neoplastic lesions, either intestinal 
adenomas or flat ductal lesions arising from different areas of the ampullary region 
(Esposito et al. 2001; Kaiser et al. 2002; Ruemmele et al. 2009; Stolte and Pscherer 2009). 
There are areas of residual adenoma in 30-90% of ampullary adenocarcinomas, indicating 
that there is an adenoma-carcinoma sequence involved in these neoplastic lesions (Kozuka 
et al. 1981; Fischer and Zhou 2004). The most commonly discovered premalignant lesions 
are adenomas of the intestinal type, which share traits with other intestinal adenomas in the 
large and small bowel. These are tubular, villous or tubulovillous adenomas. The natural 
history of ampullary adenomas have not been determined in detail, but there are apparent 
similarities to that of colorectal adenomas (Lieberman et al. 2012; Zauber et al. 2012) 
indicating a similar adenoma-carcinoma pattern (Baczako et al. 1985; Yamaguchi and 
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Enjoji 1991; Wittekind and Tannapfel 2001). The continuum from a premalignant lesion, 
which over time (years) develops into invasive carcinoma warrants that also these 
premalignant lesions have to be resected in a similar way like colorectal adenomas do 
(Heidecke et al. 2002; Chini and Draganov 2011),   
Figure 7.  
Neoplastic lesions are rare in the small intestine, but when present, they have a predilection 
to occur in the vicinity of the duodenal papilla (Wagner et al. 2008). As described above, 
the ampullary region is a complex anatomical and histological area where the intestinal 
mucosa meets pancreatobiliary epithelium, and neoplasia can originate from any of these 
locations. Ampullary adenocarcinoma accounts for 6% of all periampullary and pancreatic 
malignancies (Okano et al. 2014) and 0,5% of all gastrointestinal malignancies. 
Depending on the origin and growth pattern of the tumors are ampullary adenocarcinomas, 
classically, subdivided into three categories depending on the origin of the lesion, 
(peri)ampullary, intra-ampullary or mixed (Cubilla and Fitzgerald 1980). The classical 
categories have in recent years, been remodeled to suit better the different premalignant 
lesions that originate from the various locations in the ampullary region. Adsay et al (2012), 
proposed a classification with four different categories instead, also including descriptions 
of the preinvasive lesions for each location, which can undergo malignant transformation, 
Figure 8. The classification proposed by Adsay et al. (2012) is adopted, with minor 
revision, in the latest version (4.0.0.0) of the College of American Pathologists (CAP) 
protocol to be used in the U.S., when examining resected ampullary lesions (Kakar et al. 
2017).  
Figure 7. Examples of ampullary neoplasia at endoscopy.
A and D Ampullary adenoma. B and C, Ampullary adenocarcinomas. 
A B
C D
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1.6.2 Classification of ampullary neoplastic lesions 
1.6.2.1 Intra-ampullary papillary-tubular (IAPN) neoplasia or Intra-AMP 
Intra-AMP tumors originate from mucosal components within the ampulla and can 
sometimes extend out through the patulous ductal opening into the duodenal lumen with 
friable tissue material. The lesions share many similarities with intraductal papillary 
mucinous neoplasm (IPMN) or intraductal tubulopapillary neoplasms (ITPN) of the 
pancreatic ducts and also intraductal papillary neoplasm (IPN) of the biliary tree (Ohike et 
al. 2010). 
IAPN lesions can undergo malignant transformation in a similar way to IPMNs and 
progress with invasive growth (Adsay et al. 2016). The predominant cell types of the 
preinvasive lesions are either of intestinal, gastric, or pancreatobiliary differentiation (Pant 
et al. 2018). At endoscopic examinations, they might be hard to discern as they, in their 
non-invasive state, seldom grow out on the duodenal surface, and at least 75% of the 
lesions should be inside the ampulla to define them as an IAPN. Invasive malignancies that 
develop from IAPNs can either be of the intestinal or the pancreatobiliary type. IAPN 
lesions can correspond to the intramural protruding lesions described by Yamaguchi et al. 
(1990).  
Figure 8. The four distinct types of ampullary region carcinomas. Discernable through the 
distribution of the preinvasive (grey areas) and invasive (black areas) components. 
From: Adsay,	V.,	Ohike,	N.,	Tajiri,	T.,	et	al.,	(2012)	Ampullary	Region	Carcinomas:	Definition	and	Site	
Specific	Classification	With	Delineation	of	Four	Clinicopathologically	and	Prognostically	Distinct	
Subsets	in	an	Analysis	of	249	Cases,	the	American	Journal	of	Surgical	Pathology, 36,	11,	1592-1608.	
https://dx.doi.org/10.1097/pas.0b013e31826399d8	
Reprinted	with	permission	from	Wolters	Kluwer	Health	Inc.
1.6.2.2 Ampullary-ductal lesions or AMP-ductal 
Ampullary-ductal lesions are plaque-like thickenings of the wall inside the ampulla and 
might be mistaken for fibrosis but are scirrhous constrictive carcinomas. They have no 
distinct premalignant precursor lesion. Ampullary-ductal lesions are also difficult to notice 
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from the duodenal surface. They might just be a slightly elevated or small, retracting 
ulcerating at the papilla from the duodenal side. The tumors are pancreatobiliary type 
lesions and can be classified as T3b (or T4 in TNM ver.7) even though they are small due 
to the anatomical proximity to the peripancreatic soft tissues in the posterior wall of the 
ampulla (Adsay et al. 2012a). Ampullary-ductal lesions share characteristics with other flat 
lesions in the pancreatobiliary ducts such as PanIN and BilIN (Krishnamurthy and 
Sriganeshan 2019). 
1.6.2.3 (Peri)Ampullary-duodenal lesions 
Exophytic, classical, intestinal tumors, arising from the duodenal surface of the ampulla. 
They are in many ways like non-ampullary small intestinal adenomas and colonic 
adenomas. They are frequent in patients with familial adenomatous polyposis (FAP), and 
have, by definition, at least low-grade dysplasia (Dhall et al. 2015). Areas of ulceration are 
typically areas of invasiveness. They are of intestinal differentiation and endoscopically 
they correspond to the exposed protruding or ulcerating tumors described by Yamaguchi et 
al. (1990). 
1.6.2.4 Ampullary NOS (not otherwise specified) lesions 
Tumors found at the papilla of Vater, in-between the ampulla and the ampullary-duodenal 
areas in an unspecified manner. Ampullary-NOS is the most common location for 
ampullary neoplasia, according to Adsay et al. (2012a). The tumors can have an intestinal, 
pancreatobiliary, or a mixed type of histopathological differentiation and is endoscopically 
probably equivalent to the exposed protruding variant (Yamaguchi et al.1990).  
1.6.3 Histopathological staging of ampullary adenocarcinoma 
The AJCC/UICC TNM classification has recently been updated from version 7 (Edge et al. 
2009) to version 8 (Amin et al. 2017) with several changes in the classification for 
ampullary cancer, Table 1. The seventh version of the classification was not so elaborate 
for ampullary cancer and had several weaknesses. One of the weaknesses was concerning 
the unprecise term “duodenal wall” used for T2 tumors. Tumors originating on the 
duodenal surface of the papilla, they should probably have been staged according to the 
TNM for small intestinal tumors, not as ampullary tumors (Adsay et al. 2012b). Invasive 
tumors that originate in the ampullary-duodenal area are, in the seventh TNM version, 
viewed as T2 regardless of how small they are as they invade the “duodenal wall“ per 
definition (You et al. 2014). 
Whereas, an intra-ampullary tumor that grows from the inside out thru the duodenal wall 
also will be staged as a T2, but probably is a much larger tumor and a more aggressive 
tumor. Perhaps will the inclusion of several new T-stages, in the eight version, that 
resemble the TNM definitions for small intestinal tumors help in staging these tumors more 
correctly.  
Furthermore, at histopathological examination is staging of ampullary malignancies not 
easy, regardless of the weaknesses of the tumor classification, due to the intricate anatomy 
of the ampullary region, with several epithelial surfaces and the variation in the underlying 
tissues next to the epithelial surfaces. Another example of a problem in the seventh version 
of the TNM classification is that in many patients are the posterior wall of the ampulla not 
covered by pancreatic parenchyma, making even small tumors, invading out through the 
ductal wall, to be classified as T4 , because they invade the peripancreatic soft tissues. This 
classifications does not mirror the prognosis of the lesion, and at the same time they could 
never be classified as a T3 tumors as there is no pancreas to invade in that direction (Adsay 
et al. 2012b). 
The discussion regarding the staging system for ampullary adenocarcinomas continues as 
both Kim et al. (2018) and Imamura et al. (2019) have demonstrated weaknesses of the 
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eighth TNM version, with, in some instances, no difference of overall survival between 
neighboring T-stages. 
In the seventh TNM version, there was a reversed survival between T1N0 and T2N0 
cancers among the 4,328 patients with ampullary cancer in the AJCC database (Adsay et al. 
2012b). Where 5-year survival of T1N0 was 39.7% and for T2N0 43.7%. 
The problems with the TNM classification of ampullary tumors must be considered when 
comparing recent studies with older ones. In the US is the eighth edition mandatory from 
January 1, 2018 while other countries still use the seventh version. 
Table 1. The development of the TNM-classification from version 7 to version 8. 
T-
category 
Ampulla of Vater tumors 
T-criteria version 7
Small intestine /duodenal tumors 
T-criteria version 7
Ampulla of Vater tumors 
T-criteria version 8
T0 No evidence of primary 
tumor 
No evidence of primary tumor No evidence of primary tumor 
Tis Carcinoma in situ Carcinoma in situ Carcinoma in situ 
T1 Tumor limited to ampulla of 
Vater or Sphincter of Oddi 
T1a Tumor invades lamina priopria Tumor limited to ampulla of Vater 
or Sphincter of Oddi 
T1b Tumor invades the submucosa Tumor invades beyond the 
sphincter of Oddi and /or into the 
duodenal submucosa 
T2 Invades duodenal wall Invades muscularis propria Invades muscularis propria of 
duodenum 
T3 Tumor invades pancreas Tumor invades through the 
muscularis propria into the 
subserosa, or extends into 
nonperitonealized 
perimuscular tissue without serosal 
penetration 
T3a Tumor directly invades the 
pancreas (up to 0.5 cm) or  
T3b Tumor extends more than 0.5 cm 
into the pancreas, or extends into 
peripancreatic or periduodenal 
tissue or duodenal serosa without 
involvement of the celiac axis or 
superior mesenteric artery 
T4 Tumor invades 
peripancreatic soft tissues, 
or other adjacent organs or 
structures 
Tumor perforates the visceral 
peritoneum or directly invades 
other organs or structures (for 
duodenum, invasion of the 
pancreas or bile duct) 
Tumor involves the celiac axis, 
superior mesenteric artery, and/or 
common hepatic artery, irrespective 
of size 
1.6.4 Prognostic factors in ampullary adenocarcinoma 
Besides the AJCC/UICC stages of the tumors there are there several other important 
prognostic factor that influence the overall prognosis for the patients with ampullary 
adenocarcinoma. 
1.6.4.1 Pancreatobiliary or Intestinal histopathological subtype 
Tumors arising from in the ampullary region show differences in their histopathological 
phenotype and are classified as either of intestinal or pancreatobiliary subtype (Kimura et 
al. 1994). There is evidence that the differentiation of ampullary adenocarcinomas as either 
the intestinal or the pancreatobiliary type has an impact on prognosis, with the 
pancreatobiliary having a more dismal prognosis (Chang et al. 2013; Westgaard et al. 2013; 
Williams et al. 2016). A recent meta-analysis also confirmed that there is an inferior overall 
survival and disease-free survival if the lesion is of the pancreatobiliary type (Zhou et al. 
2017). Additionally, there are data indicating that the different histopathological subtypes 
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have different sensitivity to oncologic therapy (Schiergens et al. 2015; Ramaswamy et al. 
2019). 
Although there is clearly a worse prognosis for pancreatobiliary type of tumors, for the 
pathologist it is sometimes difficult to distinguish between these two subtypes. In several 
reports, there are also a mixed or “other” subtype included when classifying ampullary 
tumors into the histopathological subtypes. There is also a considerable variation in the 
reported frequency of the different subtypes, sometimes with the pancreatobiliary being the 
most frequent and sometimes the intestinal (Perysinakis et al. 2014, Zhou et al. 2017). 
Furthermore, in a report by Reid et al. (2016) was the interobserver agreement only fair 
(k=0.39) between different pathologists when determining the histological subtype. They 
also noted that many of the tumors had a mixed histological type that could be further 
subdivided into mixed-predominantly intestinal and mixed-predominantly pancreatobiliary, 
making the prognostic value difficult to interpret and also that different parts of the same 
tumor could display these different patterns.  
All these issues have made immunohistochemical analysis even more interesting, to be able 
to separate the tumors into the different subtypes. The use of different palettes of tissue 
markers that can help in discerning the histopathological subtype (Ang et al. 2014) have 
been suggested. How to interpret these and to decide on which is the best tissue markers to 
use is still under debate (Kim et al. 2019). Perhaps even using mutational analysis to 
separate the tumors into the different histopathological subtypes (Chang et al 2013; Perkins 
et al. 2019; Harthimmer et al. 2019).  
Considering these various aspects, it is hard to draw any firm conclusions on the 
importance of the histopathological subtype of ampullary adenocarcinoma and there are 
reports that state that there is no clear difference in prognosis (Lothe et al. 2019). Rather, 
different clinical scoring systems taking factors such as co-morbidity, age, TNM stage, 
tumor size and tumor differentiation into account also has been shown to have a prognostic 
value (Colussi et al. 2015; Li et al. 2019).  
1.6.4.2 Lymph nodal metastasis 
The presence of nodal metastasis after curative resection of ampullary adenocarcinoma 
portends a bad prognosis. In the eighth versions of TNM classification, is the nodal status 
divided into three levels instead of two, to better reflect the worsening prognosis of a more 
extensive lymph node involvement (Pomianowska et al. 2013; Kim et al. 2018). Not only 
the number of affected nodes is of importance but also the number of investigated nodes, 
the Lymph Node Ratio (LNR) (Roland et al. 2012; Doepker et al. 2016). The risk for lymph 
node metastasis is dependent on pathological diffrentiation of the tumor, T-stage, tumor 
size and histopathological subtype (Winter et al. 2010; Adsay et al. 2012a; Askew and 
Connor 2013; Okano et al. 2015; Moekotte et al. 2019). Due to the difficulties mentioned 
above, on T-staging in the ampullary region is the lymph node involvement already at T1 
tumors, according to several reports, between 30-50% (Hornick et al. 2011; You et al. 
2014; Amini et al. 2015). 
1.6.4.3 Mutational status of KRAS in ampullary neoplasia 
Mutations in the different RAS oncogenes, HRAS, KRAS, and NRAS are frequent in 
several malignancies, where KRAS is the most often mutated among them. RAS-genes 
influence a GDP-regulated system controlling the mitotic activity in cells (Jayaramayya et 
al. 2018; Waters and Der 2018).  
In pancreatic cancer (PDAC), nearly all tumors express mutated KRAS, and it is an 
initiating mutation in the development of PDAC (Schönleben et al. 2009). In ampullary 
neoplasia is the situation more complicated. The frequency of mutated KRAS differs in but 
the overall frequency of mutated KRAS in ampullary carcinoma is between 30%-67% 
(Chung et al. 1996; Schultz et al. 2012; Valsangkar et al. 2015; Harthimmer et al. 2019), 
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and on par with the frequency of mutated KRAS in colorectal cancer (Arrington et al. 
2012). 
Over the last decade has an array of different immunohistochemical and molecular markers 
been assessed to characterize ampullary adenocarcinoma more closely. Among these is 
mutated KRAS a crucial genetic marker that is often associated with poor prognosis 
(Schultz et al. 2012; Mafficini et al. 2018) and also seems to occur at an early stage of 
tumor development as the frequency of mutated KRAS is independent of T-stage 
(Matsubayashi et al. 1999) and are even frequent, 54%, in adenomas adjacent to invasive 
carcinomas (Howe et al, 1997). The latter finding might say that evaluating mutational 
status of KRAS could be an early sign of poor prognosis and could serve as a useful tissue 
marker during the preinterventional investigations. 
1.7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY 
Endoscopic retrograde cholangiopancreatography or abbreviated ERCP, is an endoscopic 
interventional procedure in the biliary and pancreatic ductal system. ERCP is used to 
diagnose and treat many different diseases in the pancreatobiliary system. 
Dr. William S. McCune was the first to perform what we now call ERCP. He was the first 
to cannulate the bile duct and with the use of a fiberoptic endoscope that had both frontal 
and side optics (McCune et al. 1968). A few years earlier, Dr Basil Hirschowitz (1961), was 
the first to visualize the duodenum through a fiberoptic endoscope as he presented his 
pioneering work with the first clinically useful flexible fiber-optic gastroscope. Later, 
Watson (1966), from the Glasgow Royal Infirmary, was the first to describe that he had 
visualized the papilla through an endoscope in five patients — confirming his findings by 
injecting secretin and witnessing the outflow of pancreatic juice and the movements of the 
sphincteric mechanism. 
An explosive development of the fiberoptic duodenoscopes and ERCP techniques started 
and soon came the first larger patient series (Oi et al. 1969; Cotton 1972; Demling et al. 
1972). Only a few years later, was the ERCP technique used for the first endoscopic 
interventional modality in the pancreatobiliary system, as the first endoscopic 
sphincterotomy and stone extraction was described simultaneously in Germany (Classen 
and Demling 1974) and Japan (Kawai et al. 1974).  
Today, the ERCP technique has developed into a separate field of pancreatobiliary 
interventional endoscopy that in several respects, border to surgical interventions. The 
diagnostic part of ERCP has been replaced by more sophisticated, non-invasive imaging 
modalities such as magnetic resonance cholangiopancreatography (MRCP) and 
multidetector computed tomography (MDCT). During the ERCP procedure is it possible to 
diagnose and remove all kinds of ductal stones, drain obstructed ducts, perform intra-ductal 
investigations (Spyglassä), tumor resections, and ablations as well as extensive tissue 
sampling and more. Especially the single use cholangioscopy technique has revolutionized 
biliopancreatic diagnostics, opening up a new field of intra-ductal endoscopy (Arnelo et al. 
2014; Tyberg et al. 2019).  
1.7.1 Cannulation during ERCP 
Since the beginning of ERCP, one of the significant difficulties to overcome has been the 
ability to manage transpapillary cannulation of the desired duct, most frequently the bile 
duct, safely and effectively (Cotton et al. 1972; Freeman and Guda 2005; Testoni et al. 
2016; Hawes and Devière 2018; Berry et al. 2019). Bile duct cannulation can be a technical 
and time-consuming challenge that traumatize the papilla, a situation that is well known to 
increase the risk for complications (Testoni et al. 2011).  
Somewhere between 5-20 % of biliary cannulations of a naïve papilla fail altogether, 
leaving the patient untreated and at increased risk for complications (Enochsson et al. 2010; 
Swan et al. 2011; Sheppard et al. 2015)  
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Several different chemical (Barrie et al. 2006; Fang et al. 2018), medical (Devereaux et al. 
2002) and technical suggestions (Tse et al. 2012; Noel et al. 2013; Swahn et al. 2013; 
Huang et al. 2015) have been brought up, trying to facilitate biliary cannulation, and 
thereby decrease the risk for complications (Andriulli et al. 2007; Dumonceau et al. 2014). 
1.7.2 Definitions of difficult cannulation 
There are several studies and guidelines (Freeman et al. 1996; Dumonceau et al. 2014; 
Chandrasekhara et al. 2017) that emphasize that cannulation difficulties are among the 
leading risk factor for complications, and especially post- ERCP pancreatitis. Despite this 
fact, there has not been any standardized definition of difficult cannulation, until recently. 
Freeman et al (Freeman et al. 1996) suggested a grading system for cannulation difficulties 
based on the number of attempts made at cannulation. Easy cannulation defined as 1 to 5 
attempts, moderate, 6 to 15 attempts, and difficult cannulation as more than 15 attempts. 
The proposed grading never received any broader recognition. 
Table 2. Various definitions of difficult cannulation 
Definition of difficult cannulation 
(variables used) 
Patients with difficult 
cannulation 
Time 
(min) 
Attempts Times in 
PD 
Study 
group 
(n) 
Difficult 
cannulation 
 (proc.) 
Yoo et al. 2013 >10 >10 1394 7.4% 
Mariani et al. 2016 >5 3 3940 31% 
Swan et al. 2013 >10 >10 >4 464 15.7% 
Zhou et al. 2006 >10 3 948 9.6% 
Sugiyama et al. 2017 >15 >3 423 26% 
Ismail et al. 2019 >5 >5 >1 821 37.9% 
Watanabe et al. 2019 >5 589 41.8% 
Testoni et al (Testoni et al. 2010) showed that ten attempts or more led to the highest odds 
ratio (OR 14.9, 95% CI 10.50-21.26) for PEP, among all the risk factors in their study. 
Zhou et al. concluded that five attempts also increased the risk for PEP significantly (Zhou 
et al. 2011). Several different definitions of difficult cannulation have been used over the 
years. Some of the more recently used can be seen in Table 2. Many of the definitions have 
been used in studies evaluating different cannulation techniques to be used after 
cannulation has become difficult.  
The ERCP study group of the Scandinavian Association for Digestive Endoscopy (SADE), 
were the first to perform a more extensive multi-center study measuring bile duct 
cannulation and focusing on constructing a definition of difficult cannulation based on 
prospective data (Halttunen et al. 2014). Ten endoscopy units in the Nordic countries took 
part in the study. They evaluated bile duct cannulation on 907 patients with a naïve papilla, 
to determine a definition of difficult cannulation based on the factors: time, number of 
cannulation attempts, number of guidewire passages into PD and frequency of PEP. The 
definition of a cannulation attempt was, “the intentional, continuous contact with the papilla 
with a cannulation catheter or sphincterotome”. At the first intentional cannulation contact 
with the papilla, a stopwatch was started, and the time points when cannulation techniques 
changed and when bile duct cannulation was reached were recorded. 
Halttunen et al. (2014) reported that the frequency of PEP after five attempts was 11.9% 
and when cannulation succeeded at the first attempt, the PEP frequency was only 0.6%. The 
longer the cannulation continued the higher the risk of PEP. If cannulation took less than 2 
minutes, the PEP frequency was 1.6%, and it was over 15% if cannulation took between 6 
to 10 minutes. The authors also set a cut-off time at 5 minutes that in their study 
corresponded to a PEP frequency of 2.6% if cannulation time was under 5 minutes to 
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11.8% if it was over 5 minutes. With two or more passages of the guidewire into the 
pancreatic duct, the frequency of PEP increased to over 13%. Therefore, the definition of 
difficult cannulation presented by the SADE group, using a PEP frequency of over 10% as 
the defining factor, is, after 5 minutes, after 5 attempts or at >1 passage of a guidewire into 
the pancreatic duct. The definition has since then been endorsed by the European Society of 
Gastrointestinal Endoscopy (ESGE) and is the one recommended to use when performing 
studies on cannulation difficulties (Dumonceau et al. 2014). 
1.7.3 Acute post-ERCP pancreatitis (PEP) 
Acute post-ERCP pancreatitis (PEP) is the most frequent post-interventional complication 
after ERCP. The incidence of PEP differs in large metanalyses from 3.5 % (Andriulli et al. 
2007) to 9.7% (Kochar et al. 2015).  
The definition and severity grading of PEP used in the vast majority of reports are the 
definition put together during a consensus meeting by Cotton et al. (1991), “Clinical 
pancreatitis; amylase at least three times normal more than 24 hours after the procedure that 
requires hospital admission or prolongation of planned admission”. The term, clinical 
pancreatitis, is mostly interpreted as new or worsening of abdominal pain (Freeman et al. 
2001), not to confound the complication registration with patients who either have no pain 
or have pancreatitis already before the ERCP. Hyperamylasemia can also be measured in 
up to 46% of the patients after ERCP, and it has been argued that the amylase level should 
be set higher, to 5 times the normal value, because of the hyperamylasemia that can 
continue even after 24 h in asymptomatic patients and some patients with three times 
normal values at 24 h does not have pancreatitis-like abdominal pain (Testoni et al. 1999, 
2000).  
Most patients who develops PEP have a mild to moderately difficult pancreatitis that 
subsides with supportive measures in a few days. Kochar et al found in their meta-analysis 
that the mortality after PEP was 0,7% when aggregating data from several randomized 
trials (Kochar et al. 2015).  
The grading used in the consensus criteria (Cotton et al. 1991) to grade post-ERCP-
pancreatitis’ severity is not the same grading system as the most frequently used system for 
severity grading in other kinds of acute pancreatitis, the Atlanta criteria (Banks et al. 2013). 
The consensus criteria, used in ERCP studies, focus on the length of hospital stay, the 
Atlanta criteria, instead, are based on systemic or local complications to grade severity and 
predict overall outcome after pancreatitis. A recent study by Smeets et al (2019) evaluated 
13384 patients after ERCP and graded severity of PEP according to both systems to 
determine their ability to predict mortality and PEP severity. They concluded that the 
Atlanta classification was superior in measuring PEP severity and predicting mortality, but 
the consensus criteria were better in diagnosing pancreatitis associated with ERCP.  
Patients in Sweden, with ASA 1-2, treated because of common bile duct stones with ERCP 
have an all-cause mortality within 30 days of 0.2% to 0.7% after ERCP in a Swedish ERCP 
registry (Enochsson et al. 2010). Similar mortality numbers (0.33%, 95%CI 0.24-0.42%) 
was presented in a systematic review by Andriulli et al. (2007).  
1.7.4 Other complications after ERCP 
There are several other complications after ERCP, but none of them as frequent as PEP and 
not connected to cannulation difficulties in the same way. Post-interventional bleeding 
occurs in 0.9-1.3% of the patients (Andriulli et al. 2007; Enochsson et al. 2010) and 
infectious complications with either cholangitis or cholecystitis afflicts 1.4% (Andriulli et 
al. 2007). A serious but rare complication is perforation of the duodenum. The risk for 
perforation is highest during sphincterotomy or the dilatation of strictures. Duodenal 
perforation happens in 0,3-0,6% of the ERCPs (Kochar et al 2015; Enochsson et al. 2010). 
Berzin et al (2011) in their study on procedural sedation during ERCP, had remarkably high 
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(21%) frequency of sedation related adverse events. Desaturation was the most common 
complication.  
1.7.5 Risk factors for PEP 
Several different patient-related, endoscopist-related and procedure-related factors 
increase or decrease the risk of PEP, Table 3. Among the patient-related risk factors, 
recent systematic reviews conclude that female gender, previous acute pancreatitis, 
previous PEP as well as suspected sphincter Oddi dysfunction are to be considered 
definitive risk factors for PEP (Dumonceau et al. 2014; Ding et al. 2015; Chandrasekhara 
et al. 2017). There are also probable risk factors where the evidence is conflicting 
regarding what kind of influence they have on PEP frequency, such as younger age (Chen 
et al. 2014), non-dilated bile ducts (Nakeeb et al. 2016), absence of chronic pancreatitis 
(Freeman et al. 2001), normal serum bilirubin (Dumonceau et al. 2014). 
Moreover, the influence of endoscopist experience and annual case volume on the risk of 
PEP is not entirely conclusive (Testoni et al. 2010). The success rate of the ERCP is 
dependent on experience, but experience seems not to affect complication rates (Cotton et 
al. 2009). 
Table 3. Risk factors for post-ERCP pancreatitis
Odds Ratios (95% CI) 
Definitive Patient-related 
risk factors 
Chen et al 
2014 
Ding et al 
2015 
Dumonceau et al 
2014 
Suspected SOD 2.69 (2.14-3.37) 2.04 (1.78-2.33) 1.91 (1.37–2.65) 
Female Gender 1.40 (1.24-1.59) 1.46 (1.30-1.64) 3.5  (1.1–10.6) 
Previous Pancreatitis 1.66 (1.38-2.00) 2.90 (1.87-4.48) 2.46 (1.93–3.12) 
Previous PEP 3.65 (2.76-4.82) 2.03 (1.31-3.14) 8.7  (3.2–23.86) 
Suspected Patient-related 
risk factors 
Younger Age (<60) 2.14 (1.41-3.25) 1.22 (0.98-1.52) 
Absence of chronic pancreatitis 1.87 (1.00 – 3.48) 
Normal serum bilirubin 1.89 (1.22 – 2.93) 
Definitive Procedure-related 
risk factors 
Difficult cannulation (various definition) 3.49 (1.36-8.93) 1.76 (1.13 – 2.74) 
Pancreatic guidewire passages >1 2.77 (1.79 – 4.30) 
Pancreatic injection 1.62 (1.31-1.99) 2.2  (1.60 – 3.01) 
Suspected Procedure-related
risk factors 
Pre-cut sphincterotomy 2.11 (1.72-2.59) 2.30 (1.85-2.85) 2.3  (1.4 – 3.7) 
Pancreatic sphincterotomy 3.07 (1.64 – 5.75) 
Balloon dilatation of an intact papilla 4.51 (1.51 – 13.46) 
There is a list of procedure-related risk factors as well, Table 3. The definite risk factors 
are, according to ESGE guidelines (Dumonceau et al. 2014) different aspects of difficulties 
during cannulation, such as long cannulation time (>10min or >5 min) (Halttunen et al. 
2014), pancreatic guidewire passages >1 time and contrast-injection into the pancreatic 
duct. The probable technical risk factors are pre-cut sphincterotomy, pancreatic 
sphincterotomy and biliary balloon dilatation without prior sphincterotomy. Some reports 
state that cannulation using pre-cut technique is not a risk factor, perhaps even the opposite 
if done early in the cannulation process (Navaneethan et al. 2014; Sundaralingam et al. 
2015; Takano et al. 2018)  
The risk for PEP in a single patient, who has several risk factors for PEP is the sum of all 
the risk factors and can, therefore,  become as high as 40% in extreme cases (Freeman et al. 
2001). 
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There is also a long list of likely risk factors but there are conflicting results regarding 
those. 
Several guidelines agree that difficult cannulation is a significant risk factor (Tenner et al. 
2013; Dumonceau et al. 2014; Chandrasekhara et al. 2017). 
1.7.6 Methods to reduce the risk for post-ERCP pancreatitis 
1.7.6.1 NSAIDs during the procedure 
During the last decade, several trials have investigated the effect of NSAIDs on the risk of 
developing PEP with sometimes conflicting results (Elmunzer et al. 2012; Lua et al. 2015; 
Leerhøy et al. 2016). But when combining data from several randomized controlled studies 
in meta-analyses the results clearly indicates that rectal administration of either 
indomethacin or diclofenac as a single dose at the time of ERCP can reduce the risk of 
developing PEP from 13% to 6.8% (Serrano et al. 2019) and the RR for developing PEP 
0.52 (95% CI 0.43-0.64)  (Yang et al. 2017; He et al. 2018). It is recommended to use 
NSAIDs to reduce the risk of PEP in several international guidelines (Tenner et al. 2013; 
Dumonceau et al. 2014; Chandrasekhara et al. 2017). 
1.7.6.2 Guidewire cannulation technique 
Transpapillary cannulation can be done without a guidewire, using a catheter and contrast 
injections to guide cannulation, or with a guidewire to lead the way during cannulation, 
Figure 9. A meta-analysis including 12  randomized trials with a total of 3450 patients, 
showed a decrease in PEP rate (RR 0.51; 95% CI, 0.32-0.82) and a higher cannulation 
success rate (RR 1.07; 95% CI, 1.00-1.15) (Tse et al. 2012). There are also indications that 
if the endoscopist controls the guidewire themselves, instead of the assistant, is the risk for 
inadvertent guidewire passage into the pancreatic duct diminished (Buxbaum et al. 2016). 
Although guidewire led cannulation now dominates among cannulation techniques (Adler 
2018) it is an ongoing discussion if guidewire passages into the pancreatic duct might even 
lead to a higher risk for PEP than what the injection of contrast medium into the pancreatic 
duct does (Mariani et al. 2012; Srinivasan and Freeman 2016). 
Figure 9. Contrast guided cannulation and guidewire guided cannulation. 
From: Löhr, J., Aabakken, L., Arnelo, U., et al. (2012). How to cannulate? A survey of the Scandinavian 
Association for Digestive Endoscopy (SADE) in 141 endoscopists. Scandinavian journal of gastroenterology 
47(7), 861-9. https://dx.doi.org/10.3109/00365521.2012.672588 
Reprinted by permission of Taylor & Francis  
Artist, Dr Fredrik Swahn 
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1.7.6.3 Prophylactic pancreatic duct stenting 
Several meta-analyses have shown a clear reduction in PEP rate with prophylactic 
pancreatic stenting (OR, 0.22 to 0.39), particularly when faced with a patient at an elevated 
risk for PEP (Mazaki et al. 2010; Sugimoto et al. 2019). Prophylactic pancreatic duct 
stenting is recommended in cannulation situations when the guidewire has been inside the 
pancreatic duct. The diameter of the stent should be 5 Fr and not 3 Fr (Afghani et al. 2014) 
and be left in place after the procedure for at 7 to 10 days (Cha et al. 2013). If the 
endoscopist chooses to use pancreatic stents without internal flanges, the recommendation 
is to perform an X-ray within two weeks to confirm the dislodgement of the stent and 
diminish the risk for stent induced complications (Bakman et al. 2009). However, there are 
indications that the risk for complications is not increased with a slightly longer interval 
than two weeks before the removal of retained stents (Dultz et al. 2018). In a Japanese 
randomized controlled study, where they used 5 Fr , 3 cm  straight stents with no internal 
flanges, they noted that 96% of the stents had dislodged in a mean time of 2 days and also 
that there was a 3.2 % PEP frequency in the stent group compared to 13.6% in the non-stent 
group (Sofuni et al. 2007). 
1.7.6.4 Rendez-vous cannulation 
In order to facilitate bile duct cannulation, the assistance of a guidewire, placed in an 
antegrade direction out through the papilla into the duodenum, has proven to be a useful 
technique (Tse et al. 2012; Noel et al. 2013; Swahn et al. 2013a; Huang et al. 2015). The 
guidewire can be placed either during a concomitant laparoscopic cholecystectomy 
(Deslandres et al. 1993; Noel et al. 2013), percutaneously (Dowsett et al. 1989) or using 
EUS to puncture the bile duct (Iwashita et al. 2011; Bill et al. 2016) After that catching the 
guidewire with a snare, pulling it out of the endoscope and threading on the sphincterotome 
for an unproblematic cannulation.  
1.7.6.5 Other prophylactic measures against PEP 
There is a lengthy list of different substances and treatment alternatives that have been used 
trying to prevent PEP in some cases with interesting results and in others more uncertain 
findings. Protease inhibitors might be useful (nafamostat) (Ohuchida et al. 2015), topical 
epinephrine spray in combination with Indometacin showed no difference (Kamal et al. 
2019) , heparin injections given in 3 doses at the time for ERCP and the day after showed a 
biochemical effect on amylase levels (Ung et al. 2011), somatostatin injection can be useful 
for high-risk patients (Wang et al. 2018), glyceryl trinitrate sublingually or sprayed 
topically in the duodenum can have some effect on PEP frequency (Ding et al. 2013), and 
aggressive hydration during and after the ERCP might be the most exciting suggestion and 
has promise to be a useful method, at least in high-risk patients (Radadiya et al. 2019). 
1.8 EVALUATION OF SUSPECTED NEOPLASTIC LESIONS IN THE PAPILLA 
The preinterventional staging of a suspected ampullary neoplastic lesion is not easy (Askew 
and Connor 2013). However, with the possibility of an endoscopic resection, avoiding 
major surgery, has the importance of a correct staging of small, non-invasive lesions been 
emphasized (Zbar et al. 2012; Alvarez-Sánchez and Napoleon 2016). There are several 
diagnostic modalities to choose from, all with their strengths and weaknesses.  
Transabdominal ultrasound is in many patients with jaundice the first examination, but it is 
of limited use when it comes to investigating ampullary lesions, with an accuracy of as low 
as 12% (Chen et al. 2009; Jones and Necas 2018). The vital distinction to determine in the 
preinterventional investigations are if the lesion is benign or malignant. As malignant 
lesions needs to be surgically resected to be cured.  
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1.8.1 Cross-sectional imaging of ampullary lesions  
Advanced multidetector computed tomography (MDCT) is in most patients the first 
investigation for biliary tract obstruction not caused by gallstone disease. MDCT is used in 
many different investigational schemes for suspected abdominal disease, and sometimes 
even used as a screening tool in search for a diagnosis in unclear cases. Because of the wide 
indications for MDCT, has the investigation, compared with other investigational methods 
used in this context, the advantage to be able to discover signs of ampullary disease in 
asymptomatic patients or as an incidental finding (Alessandrino et al. 2015). Visualizing a 
non-invasive lesion in the ampullary region is difficult, and the differentiation between 
benign and malignant lesions is even more difficult in the ampullary region than at other 
levels of the biliary tree (Nikolaidis et al. 2014).  
Magnetic resonance imaging (MRI) is complementary to MDCT regarding the search for 
metastasis and distant lymph node metastasis, but has a better accuracy in discerning if a 
periampullary lesion is malignant or benign compared with MDCT, due to the use of the 
MR cholangiopancreatography (MRCP) technique (Andersson et al. 2004). It is unclear if 
this is true for purely ampullary lesions as the ampullary region is more challenging to 
evaluate with MRCP as it often holds lesser amounts of fluid because of the natural 
narrowing of the lumina (Geier et al. 2000). Both MRI and MDCT image quality and 
diagnostic value is highly dependent on the protocol used during the examination and the 
measures taken to distend the duodenal lumen to delineate the papilla more clearly 
(Alessandrino et al. 2015).  
1.8.2 Endoscopic ultrasonography in ampullary neoplasia  
Endoscopic ultrasonography (EUS) is used, to assess locoregional status in ampullary 
disease (Peng et al. 2019). Although there are some conflicting results, a meta-analysis 
concludes that EUS has a moderate sensitivity for T- and N-stage and concluded that EUS 
is inadequate as a single investigation to select patients for surgery or endoscopic resection 
(Trikudanathan et al. 2014), but in many instances useful in the local staging. Regarding the 
evaluation of the intraductal extension of an adenomatous neoplastic lesion, has ERCP and 
EUS similar sensitivity (Ridtitid et al. 2015). ERCP having the downside of being invasive, 
and EUS the advantage to to determine the T-stage of the lesions makes the choice of 
performing EUS on many of these patients straight forward (Gaspar and Shami 2015). One 
disadvantage being that both EUS and ERCP is dependent on skilled endoscopists to give 
the best evaluations.  
Larger size of the lesion (>20 mm) is often a sign of malignancy, and lesions smaller than 
6,5 mm are rarely malignant (Patel et al. 2016). EUS is definitively better than MDCT in 
determining the grade of local invasiveness and local nodal status and MDCT is not 
particularly useful in deciding local tumor status (Artifon et al. 2015).  
The best modality, for local staging, and to decide between invasive or non-invasive tumor, 
is intra-ductal ultrasound (IDUS) (Ito et al. 2007; Okano et al. 2013). The negative aspect 
of IDUS is that the technique is invasive and dependent or skilled operators in this unusual 
patient group (Menzel et al. 1999a).  
1.8.3 Cytology of ampullary lesions 
The use of brush cytology is the basis for tissue diagnosis of bile duct strictures and is the 
most used tissue sampling method in the investigation of bile duct strictures. Brush 
cytology is done because the ease of taking the samples during ERCP and the low costs. 
The sensitivity is in most series low (6-64%) while the specificity is close to 100% for 
diagnosing malignancy in bile duct strictures (Hacihasanoglu et al. 2018).  
To improve the sensitivity on brush cytology different methods have been tried, and the one 
that is used in routine clinical praxis is fluorescence in situ hybridization (FISH) analysis, 
that in unclear cases can increase the diagnostic yield (Kushnir et al. 2019).  
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Studies concerning the utility of brush cytology has primarily focused on biliary and 
pancreatic malignancies and not on ampullary adenocarcinomas and especially not 
adenomas in the ampulla, where only small case reports exist (Mantoo et al. 2017). The 
tissue diagnosis of ampullary lesions is to a considerable extent based on the acquisition of 
forceps biopsies not on brush cytology (Jailwala et al. 2000). Furthermore, is the 
differentiation between HGD and adenocarcinoma on brush cytology almost impossible.  
1.8.4 Endoscopic biopsies 
Histopathological evaluation of endoscopic biopsies of ampullary neoplastic lesions is not 
easy (Elek et al. 2003). The tissue samples are small and only represent a tiny fraction of a 
suspected lesion, and several factors (e.g. stents, sphincterotomy, inflammation) can 
influence the diagnostic yield making the assessment of the tissue sample even more 
challenging. It has been known that endoscopic biopsies of ampullary lesions have a low 
sensitivity to correctly diagnose malignancy (Yamaguchi et al. 1990). Furthermore, the 
inter-and intraobserver agreement, when evaluating endoscopic biopsies, is moderately 
good between different assessors to diagnose reactive atypia from lesions with low-grade 
dysplasia (Allard et al. 2018). 
There is a recommendation to take at least six biopsies (Espinel 2015) to get a higher 
diagnostic yield.  Should biopsies be taken before or after sphincterotomy? The answer is 
not clear, and it is probably best to take biopsies early during the endoscopic examination 
not to get reactive changes (Bourgeois et al. 1984, Menzel et al 1999b). But at the same 
time can increase diagnostic yield in cases of intra-ampullary lesions (Elek et al 2003). 
There has been a concern that taking biopsies from the papilla could increase the risk for 
pancreatitis after the biopsies. In a recent matched-pairs controlled study there was a non-
significant difference in complication frequency between ordinary ERCP and ERCP with 
biopsies. It is difficult to draw any clear conclusions form the study as it is probably 
underpowered with only 54 patients in each arm (Dacha et al. 2017). 
DeOliveira et al. (2006) as well as Lee et al. (2014a) noted that the endoscopic appearance 
and forceps biopsies have similar accuracy at determining if a lesion is benign or malignant, 
and that both aspects are important when evaluating ampullary neoplastic lesions.  
1.9 TREATING NEOPLASTIC LESIONS IN THE PAPILLA OF VATER 
To resect and cure sporadic neoplastic lesion in the papilla of Vater there are three different 
treatment options to choose from, pancreatoduodenectomy, transduodenal ampullectomy or 
endoscopic papillectomy. A fourth possibility is the pancreas-preserving duodenectomy, a 
surgical operation usually reserved for patients with hereditary polyposis diseases (de 
Castro et al. 2008).  
1.9.1 Pancreatoduodenectomy (PDE) (Whipple´s operation) 
1.9.1.1 History/Development 
Pancreatoduodenectomy or Whipple´s operation was presented for the first time in 1935 
(Whipple et al. 1935), Figure 10. Only limited numbers of procedures were performed 
during the early years due to the extremely high in-hospital mortality of up to 25% (Mongé 
et al. 1964). However, during the last two decades has the improvements of surgical and 
perioperative treatments lowered both morbidity and mortality to between 2-4 % in expert 
centers. Because of these progresses have the indications for PDE expanded, now treating 
even patients with premalignant diseases (Cameron and He 2015; Hata et al. 2016; 
Tingstedt et al. 2018).  
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1.9.1.2 Indications 
The indications for PDE are many and incorporates the curative treatment of all kinds of 
periampullary malignancies and nowadays even premalignant conditions not amendable for 
local resections. Even in rare instances have benign diseases such as chronic pancreatitis 
been treated with PDE. It is the golden standard against which all the other treatment 
options compare. In recent years has the indications for resection widened due to the 
introduction of neoadjuvant chemotherapy and vascular resections (Tingstedt et al. 2018; 
Roessel et al. 2018).  
Figure 10. Pancreatoduodenectomy. Resection of the head of the pancreas, duodenum and the extra-
hepatic biliary tree.  
From: Xu, J., et al. (2017). Identifying the neck margin status of ductal adenocarcinoma in the pancreatic head 
by multiphoton microscopy. Scientific Reports 7(1), 4586. https://dx.doi.org/10.1038/s41598-017-04771-w 
Reprinted according to CC-BY-4.0 
1.9.1.3 Postoperative complications 
PDE is one of the most complex gastrointestinal surgical resections (Hata et al. 2016), with 
complication rates as high as 43-90% of the patients and with severe complications 
(Clavien grade 3 or higher) in at least 30% of the patients (Clavien and Strasberg 2009; 
Sánchez-Velázquez et al. 2019). PDE is a major surgical resection essential for the long-
term survival of patients with periampullary malignancies. As many radical surgical 
resections there is also some long-term morbidity for the survivors (Chen et al. 2015). 
1.9.2 Trans-duodenal ampullectomy (TA) 
1.9.2.1 History 
Halsted (1899) was the first to describe a local resection of an ampullary tumor when he 
resected a tumor in the pancreatic head as a two-stage operation. The patient survived for 
nine months before dying of metastatic disease. Before the development of flexible 
endoscopy, it was uncommon to diagnose ampullary neoplasia that was suitable for local 
resection (Rock and Fisher 1959; Barber et al. 1960).  
1.9.2.2 Indication 
The indication for transduodenal ampullectomy is somewhere between that of endoscopic 
papillectomy and pancreatoduodenectomy. TA offers a deeper resection than EP but 
without the lymph node resection that is done during PDE, with in addition, the need for 
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continued endoscopic surveillance, Figure 11 (Line A). 
There are no universal indications accepted for TA, and Beger et al (1999) suggest that 
adenomas and superficial malignancies (pTis and pT1) that have a highly differentiated 
growth patterns are a suitable patient group (Schoenberg et al. 1998). In a more recent 
patient series, the same indications were used but restricted to patients unsuitable for 
endoscopic resection, or after failed endoscopic resection where no invasive lesion could be 
seen (Nappo et al. 2019). TA can still have a place in the treatment of ampullary neoplasia 
as a rescue after failed endoscopic resection (Schneider et al. 2016). Nevertheless, caution 
is called for in patients with malignancies > 1 cm due to the substantial risk of recurrent 
disease (Yoon et al. 2005). Yoon et al. also conclude that TA is not right for patients that 
are fit for PDE, at least not if the tumor is bigger than 1 cm.  
In the retrospective patient-series by Ceppa et al. (2013) comparing outcome from a single-
center between endoscopic resection and TA they concluded that endoscopic resection was 
equally effective to resect neoplasia but with fewer adverse events (Ceppa et al. 2013).  
Perhaps can technical developments with minimally invasive or robot-assisted surgical 
procedures change the indications for transduodenal ampullectomy in the future (Downs-
Canner et al. 2015; Chapman et al. 2018; Hong et al. 2018; Lee et al. 2019b), but at present 
has TA very few indications. 
Figure 11. The depth of resection during transduodenal ampullectomy (Line A) and endoscopic 
papillectomy (Line B). CBD, Common bile duct. PH, pancreatic head. MPD, main pancreatic duct. 
PM, proper muscle layer. SO sphinchter Oddi. D, Duodenal lumen. 
Reprinted from Gastrointestinal Endoscopy Han, J., Kim, M. Endoscopic papillectomy for adenomas of the 
major duodenal papilla (with video) 63(2),  292-301, Copyright (2006). With permission from Elsevier Inc. 
https://dx.doi.org/10.1016/j.gie.2005.07.022 
1.9.2.3 Results 
In a meta-analysis including in total 382 patients, had 93% microscopically free resection 
margins, but had 18% of the patients had a recurrent disease. A neoplastic lesion that 
recurs after TA must be considered for further surgery with PDE. Complication frequency 
was 27% and mortality 0.26%, according to the meta-analysis (Papoulas et al. 2017). 
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1.9.3 Endoscopic papillectomy (EP) 
1.9.3.1 Background 
Endoscopic resection of intestinal adenomas has been a frequent phenomenon since the 
beginning of colonoscopy (Winawer et al. 1993). Before the development of flexible 
endoscopy were benign tumors in the papilla anecdotal findings (Barber et al. 1960). 
During the development of ERCP in the 1970s and ’80s there were several documented 
findings of adenomas in the papilla of Vater (Bourgeois et al. 1984). The knowledge that 
local transduodenal resection of small neoplastic adenomatous lesions in the ampullary 
region could be a successful treatment, combined with the intense development in 
endoscopic technique, gave birth to endoscopic treatments of ampullary lesions in the 
1980s (Suzuki et al.1983; Lambert et al. 1988; Ponchon et al. 1989). However, it was not 
until the 1990’s that the development of the technique of EP started to progress, after the 
landmark series by Binmoeller et al. (Binmoeller et al. 1993). Since then, EP has developed 
into being considered the first-line treatment of small ampullary adenomatous lesions (Irani 
et al. 2009; Laleman et al. 2013; Onkendi et al. 2014; Ridtitid et al. 2014; Klein et al. 2017; 
Sahar et al. 2019). 
Figure 12. The technique of endoscopic papillectomy. a/identifying the lesion. b/cannulation of the 
pancreatic duct for methylene-blue injection. c/ Resection with snare and diathermy d/ Retrieval of 
the resected specimen. e/ Inspection of the resected area for signs of residual adenoma or signs of 
complications. f/ Prophylactic pancreatic stenting.  
Images with  permission from Dr Urban Arnelo .
1.9.3.2 Techniques in Endoscopic papillectomy 
The technique of EP is in many respects similar to that of other endoscopic snare resections 
throughout the intestine, with some technical exceptions (Palma 2014; Kandler and 
Neuhaus 2018), Figure 12. Before resection starts, attempts are made to cannulate both 
ductal systems. Primarily, cannulation of the pancreatic duct is vital to inject methylene 
blue (Poincloux et al. 2014), to ease the post-resectional placement of a PEP prophylactic 
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pancreatic stent. The bile duct can be cannulated to evaluate if there are any signs of intra-
ductal extension of the adenoma up in the ducts (Ridtitid et al. 2015). Resection is 
performed without submucosal injection if there is no lateral spreading of the tumor (Hyun 
et al. 2017). A polypectomy snare coupled with blended diathermy current is used to 
perform an en-bloc resection of the lesion.  
After retrieval of the resected specimen and hemostasis, the pancreatic duct is 
prophylactically stented (Harewood et al. 2005). The bile duct is stented in case of poor 
outflow of bile after the resection at the discretion of the endoscopist. Small islands of 
residual adenoma can be ablated with argon-plasma coagulation, and at the same time, 
treating minor bleeding spots (Nam et al 2018).  
The depth of resection at EP is, in theory, not as deep going as with TA, Figure 11. EP can 
resect lesions corresponding to line A while TA can get a bit deeper but with the need to 
reconstruct the continuity between the ductal and the intestinal mucosa with a sutured 
anastomosis. The deeper resection plays a part in the higher frequency of complications 
after TA (Nam et al. 2018). 
1.9.3.3 Indication for EP 
There are no universal indications for EP in the literature. One obvious contra-indication 
for curative EP is definite signs of invasive tumor on imaging. The ASGE guidelines from 
2015, states that ampullary lesions above four cm in size, endoscopic biopsies that show 
malignancy, an endoscopic appearance that indicates malignancy, or lesions with an intra-
ductal extension above 1 cm it is not recommended to perform EP in routine management 
(Chathadi et al. 2015). The indication for EP proposed by the ASGE is almost the same as 
what Binmoeller et al. (1993) used in the first patient series regarding EP. 
The boundary for EP has in several reports over the years been pushed further, and it has 
been shown that it is possible to even treat superficial malignant lesions with acceptable 
results (Woo et al. 2009; Yamamoto et al. 2019) or intraductal extension above 1 cm 
(Pérez-Cuadrado-Robles et al. 2018). Although these new indications must be considered 
experimental as the results are conflicting (Amini et al. 2015) and EP is not free from 
complications. More importantly, not withholding almost certain curative treatment with 
PDE in patients with small adenocarcinomas. Staging of ampullary lesions is complicated 
not only clinically but also at histopathological examination. EP has been used as a “total 
biopsy” (Ogawa et al. 2012) when the biopsies are not convincing for malignancy and the 
lesion seems to be resectable. 
With no universal and precise, indication for EP, the results from the different patient series 
that exist are conflicting, Table 4. 
Table 4. Endoscopic papillectomy, results from large patient series 
Patients Cured Complications Recurrance Need for surgery 
n n Proc. n Proc n Proc n Proc 
Binmoeller et al. 1993 25 23 92% 5 20% 6 24% 3 12% 
Catalano et al. 2004 103 83 81% 10 10% 10 10% 16 16% 
Bohnacker et al. 2005 106 73 69% 16 15% 15 14% 19 18% 
Laleman et al. 2013 91 71 78% 23 25% 13 16% 14 15% 
Ridtitid et al. 2014 182 134 74% 34 19% 16 9% NA 
Napoleon et al. 2014 93 84 90% 39 42% 5 5% NA 
Onkendi et al. 2014 139 82 59% 38 27% 44 32% 9 6% 
Klein et al. 2018 125 122 98% 31 25% 3 2.4% 3 2.4% 
Li et al. 2019b 110 86 78% 46 42% 13 12% 11 12% 
Sahar et al. 2019 128 106 83% 23 18% 8 6% 11 8.5% 
Total 1204 950 79% 286 22% 133 12% 102 11% 
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1.9.3.4 Results of the endoscopic resection 
With no universal and precise, indication for EP, are the results from different patient series 
a bit difficult to interpret as the patient selection for the intervention is not entirely clear. 
Furthermore, there is no consensus on what is to be considered a treatment success. The 
most frequently used definition is the one stated by Catalano et al. (2004); “complete 
excision of the lesion without regard to the number of sessions required and the absence of 
recurrence or recurrence during long-term follow-up that was easily treated 
endoscopically.” This relatively broad definition of treatment success has often been 
narrowed down to define recurrence as new neoplastic lesion occurring after a 3-6 months 
interval of being neoplasia free at endoscopic examination (Palma 2014). 
With these implications in mind, the frequency of curative treatment after EP is between 
46-92%, with recurrence during follow-up of between 0-33%. (Ardengh et al. 2015;
Chathadi et al. 2015). Examples from the larger patient series is displayed in Table 4.
Between 2.4% and 18% of the patients are after EP referred for surgical resection, due to
either intraductal extension or to discovering malignant transformation.
1.9.3.5 Complications 
EP has, compared to other endoscopic interventions, a high frequency of adverse events, 
with a scenario more of that of a surgical resection. The most common complications are 
bleeding (2-16%), and acute pancreatitis (5-15%). The overall frequency of adverse events 
is around 25%, but most of the complications are mild to moderate and with a mortality of 
<0.3% (Espinel 2015; Chathadi et al. 2015). 
1.9.3.6 Future for EP 
There have been several attempts at expanding the indications for EP to include patients 
with superficial malignancies (Alvarez-Sanchez et al. 2017) and intra-ductal extension One 
treatment possibility could be to manage intra-ductal extension with radiofrequency (RF) 
ablation (Valente et al. 2015; Rustagi et al. 2017). A few patient series have been published 
with promising results. Although, the treatment with RF at present is to be considered an 
adjunct to palliative treatment, but might, with more conclusive data in the future be 
considered a part of curative treatment. One prospective study with 20 patients had, after 
one year of follow-up, 70% of the patients no signs of residual adenoma (Camus et al. 
2018).  
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2 AIMS 
I. To design an endoscopic classification of the endoscopic appearance of the papilla
of Vater and to determine the inter- and intra-observer agreement among experts as
well as non-expert endoscopists when assessing the different papillae types of the
classification.
II. Determine if the endoscopic appearance of the papilla of Vater influences
transpapillary bile duct cannulation during endoscopic retrograde
cholangiopancreatography (ERCP)
III. To evaluate if endoscopic papillectomy can be performed as a safe diagnostic and/or
therapeutic procedure in biopsy-verified or suspected ampullary adenoma at the
Karolinska University hospital and to evaluate if the expression of mutated KRAS
in endoscopically resected tissue predicts long-term outcome.
IV. To investigate what symptoms and/or findings that could be of value in the clinical
decision-making and in choosing the most appropriate method to resect an
ampullary neoplastic lesion when invasive malignancy is not evident.
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3 METHODS 
3.1 PAPER I 
3.1.1 Study design 
The study is design as an inter- and intra-observer agreement study to validate a suggested 
new classification of the endoscopic appearance of the papilla of Vater among endoscopists 
with different levels of experience.  
3.1.2 Creation of the endoscopic classification  
To create the classification of the endoscopic appearance of the papilla of Vater, photos of 
140 different papillae were captured during ERCP examinations of naïve, previously 
untouched, papillae. The endoscopist took a minimum of 4 photos from 4 predefined 
positions. The first photo was captured, at full inflation, of the papilla and the surrounding 
duodenal wall from two different angles, to get a sense of the 3-dimensional arrangement. 
Followed by a close-up of the papilla and finally one frontal image with a standard 
cannulation catheter or sphincterotome positioned beside the papilla, for size reference. 
A group of expert endoscopists analyzed all the 140 sets of photographs of the different 
papillae and after discussion, agreed upon the proposed classification, of the endoscopic 
appearance of the papilla of Vater, Table 5 and Figure 13. 
Table 5. The endoscopic classification of the papilla of Vater 
Type 1 Regular Papilla, with no distinctive features, i.e., “classic appearance”. 
Type 2 Small Papilla, often flat, with a diameter not bigger than 3 mm (approx. 9 Fr). 
Type 3 Protruding or Pendulous Papilla. A papilla that is standing out protruding or 
bulging into the duodenal lumen or sometimes hanging down, pendulous with 
the orifice oriented caudally. 
Type 4 Creased or Ridged Papilla, where the ductal mucosa seems to extend distally, 
rather out of the papillary orifice, either on a ridge or in a crease. 
3.1.3 Inter- and intraobserver agreement study 
An inter- and intra-observer agreement study was constructed to validate the proposed 
endoscopic classification. The aim was to determine if the different papilla types were 
possible for both expert and non-expert endoscopists to agree with the proposed 
classification also to evaluate if their opinion was consistent over time.  
A web-based survey consisting of 50 different papillae, chosen from the original 140 
papillae used when constructing the classification. The picture-set of the individual papillae 
consisted of up to 4 photographs from the same papilla. The invitation to take part in the 
survey was sent out via e-mail to all 18 endoscopists in the Nordic countries. The web 
format was chosen to ease the distribution of the survey and to standardize the image 
quality. Also, to have a convenient interface for the respondents and the possibility for 
reminders and data collection. The option, in the web-survey, to randomly change the order 
of the multiple-choice answers as well as the order of different photo sets of the papillae 
was used. The survey started with a brief introduction to get the respondent acquainted with 
the classification and the papilla types before the proper survey started. The invitation e-
mail also included a separate document with background information on the classification 
together with image examples of the different papilla types. 
Three months later, the same endoscopists were approached to respond once more to a 
similar survey, now containing a stratified random sample of 20 different papilla photo sets 
(5 each of the four different types of papillae) from the first survey, allowing for an 
assessment of intraobserver agreement. 
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3.1.4 Kappa statistics 
Since the presentation of Cohen in 1960 (Cohen 1960), the use of kappa statistics has 
dominated in interobserver agreement studies. Kappa statistics consider the possibility of a 
chance agreement occurring between different observers and not just the rate of agreement 
per se. To calculate interobserver agreement, was the respondents’ answers to the different 
sets of papilla photos compared to the type of papilla defined for each set of photos when 
the classification was created. The analysis was performed on all respondents as a group 
compared to the correct answers, as well as the expert group, the non-expert group, and the 
individual endoscopists’ answers separately against the correct answers.  
Likewise, was the intraobserver agreement calculated, comparing the individual 
endoscopists answers against their earlier answers on the same of papilla from the first 
survey. 
Table 6. Interpretation of the kappa value 
Kappa Statistic Strength of Agreement 
<0.00 Poor 
0.00-0.20 Slight 
0.21-0.40 Fair 
0.41-0.60 Moderate 
0.61-0.80 Substantial 
0.81-1.00 Almost perfect 
To control for the situation that the endoscopists made the same mistake at both surveys, 
the answers from the second survey were also compared with the original, correct, answer 
again. The 95% confidence interval (CI) was calculated to measure the level of precision of 
the respective kappa values. The kappa value was interpreted according to Landis et al. 
(Landis and Koch 1977), Table 6.  
Figure 13. The endoscopic classification of the Papilla of Vater 
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3.2 PAPER II 
3.2.1 Study design 
This study is a non-randomized clinical trial to determine the influence the different papilla 
types, from the endoscopic classification, has on transpapillary bile duct cannulation during 
ERCP. The study group consisted of patients scheduled for ERCP with an untouched, naïve 
papilla, where bile duct cannulation was intended. The exposure was the difference in 
papilla type and the primary outcome measure was frequency of difficult cannulation.  
3.2.2 Patients  
Patients were prospectively included from nine participating centers in the Nordic 
countries. The patients had to be over 18 years old, scheduled for a clinically indicated 
ERCP, have an intact, naïve, major duodenal papilla, where the desired duct to cannulate 
was the common bile duct. 
Exclusion criteria were a papilla hidden inside a large diverticulum, a bulky tumor 
distorting the ampullary region, or patients with surgically altered anatomy. Earlier ERCP 
with stenting, sphincterotomy or patients with retrograde guidewires placed, were also 
exclusion criteria.  
3.2.3 Outcome measures 
The primary outcome measure was differences in the frequency of difficult cannulation 
distributed between the different papilla types of the newly validated classification. The 
definition of difficult bile duct cannulation used in the study was the one proposed by 
Halttunen et al, the 5-5-2 definition (Halttunen et al. 2014).  
Secondary outcome measures were cannulation failure and complications that occurred 
during the first 24 hours, or before discharge. Complications were defined according to the 
consensus criteria (Cotton et al. 1991), but the severity was not graded or complications 
that occurred after 24 hours. 
Several patient and procedure-related variables were documented. In addition to 
documenting the papilla type and the outcome measures, were data regarding the indication 
for the ERCP, the endoscopists´ experience, patient demographics, methods used during 
cannulation, and measures taken to avoid post ERCP pancreatitis (NSAIDs and/or 
protective pancreatic endoprosthesis insertion) recorded.  
3.2.4 The experience of the endoscopists 
Intuitively, there ought to be a distinct difference in frequency of difficult cannulation 
between expert endoscopists and beginners, “fellows”. To investigate the influence of 
experience on difficult cannulation and to quantify the difference, the endoscopists 
performing the cannulation was divided into three levels of experience depending on their 
lifetime accumulated number of performed ERCPs.  
Fellow endoscopists were defined as having performed less than 200 ERCPs (Jowell et al. 
1996; Faulx et al. 2017) experts were defined as having done over 1000 ERCPs and 
intermediate endoscopists 200-1000 lifetime ERCPs. To evaluate the difficulties during bile 
duct cannulation facing inexperienced endoscopists, fellows, and at the same time not to 
jeopardize patient safety, a defined time limit for the fellow endoscopists’ cannulation 
attempts had to be determined in the study protocol. The time to fulfill the definition of 
difficult cannulation was 5 minutes; therefore, this time limit was chosen for the fellow 
endoscopists to perform cannulation on their own before a more experienced colleague had 
to take over to continue the procedure.  
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3.2.5 Statistical analysis 
Power calculations were not possible in this study since the distribution of the different 
papilla types was previously unknown, as was the overall frequency of difficult cannulation 
using the ESGE approved definition. The 5-5-2 definition constructed in the report by the 
SADE study group of ERCP (Halttunen et al. 2014) consisted of expert endoscopists and 
have not previously been tested in an everyday clinical setting with endoscopists of 
different levels of experience. 
All statistical calculations were made with SPSS version 25. Chi-square test or Fisher exact 
test were used for categorical data as appropriate, as well as odds ratio calculation. Mann-
Whitney U-test was used for non-normally distributed continuous data.  
3.2.6 Ethical considerations 
The study was approved by the Ethical review board at the Karolinska Institutet. Included 
patients received no extra treatment or risk compared to standard examination. They were 
recruited because they had a clinical indication for ERCP. No extra follow-up was made 
besides controlling the medical reports for signs of complication.  
3.3 PAPER III 
3.3.1 Study design 
This study is a patient series of prospectively included patients on which EP had been 
performed at the Karolinska University hospital between 2005 and 2014. The aim was to 
evaluate the clinical outcome following endoscopic papillectomy and to incorporate an 
oncogenic evaluation of the mutational status of KRAS in the endoscopically resected 
specimen from the papilla of Vater. 
3.3.2 Patients and data collection 
All patients treated with endoscopic papillectomy, with curative intent, were included. The 
indication for resection were, if endoscopic biopsies showed adenoma or if the patient had 
an endoscopic appearance of the papilla suspicious for adenoma. Signs of invasive 
malignancy were assessed with either computed tomography (CT) or magnetic resonance 
imaging (MRI) prior to resection. Data about patient demographics, pre-interventional 
investigations, medical history, interventional techniques used, complications, the 
histopathological outcome, as well as the clinical outcome were collected and analyzed 
from the medical charts. Paraffin-embedded tissue samples from the endoscopic 
papillectomy were analyzed to determine KRAS mutational status.  
3.3.3 Outcome measures after endoscopic papillectomy 
Outcome measures for the endoscopic papillectomies were endoscopic success and post-
interventional complications. In this study, we chose the most often used definition for 
endoscopic success, proposed by Catalano et al. (2004), with minor modification. The 
definition used in the present study was that; endoscopic success was defined as complete 
excision without regard to the number of endoscopic sessions required and that the patient 
was adenoma free at two consecutive surveillance endoscopies, over a minimum period of 
6 months without recurrence during long-term follow-up.  
In contrast to Catalano et al (2004), we also included in the definition a timeframe stating 
that two consecutive, adenoma-free, follow-up endoscopies with a minimum time of 6 
months between the endoscopies had to be made to be considered cured. The use of the 
timeframe of 6 months was to clarify, more precisely, the borderline between cure and 
recurrence. 
Treatment failure was determined as an intra-ductal extension of adenoma or malignant 
transformation discovered during follow-up. A finding of neoplasia after being defined as 
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cured of adenoma was considered a recurrent disease. Postprocedural complications were 
defined according to the consensus criteria (Cotton et al. 1991).  
3.3.4 Endoscopic papillectomy technique 
All resections were performed under general anesthesia with the patient in a supine 
position. Experienced endoscopists performed all the EPs. Cannulation of both pancreatic 
and biliary ducts were tried before resection to delineate signs of intraductal extension of 
adenoma, and to install methylene blue in the pancreatic duct to ease post-resectional re-
cannulation and prophylactic pancreatic stenting (Harewood et al. 2005).  
No submucosal injection to lift the lesions were made. A braided snare, coupled with 
monopolar diathermy, was used to excise the papilla in an oral to distal direction. All 
resected tissue samples were retrieved for histopathological analysis.  
Clinical follow-up was scheduled at 1, 3, 6, and 12 months, then annually, to find and treat 
any residual adenomatous tissue or signs of recurrent neoplasia.  
3.3.5 KRAS analysis 
To determine the mutational status of the KRAS oncogene in the specimen resected at EP, 
DNA was extracted from paraffin-embedded tissue samples. In this study, we used the 
commercially available QIAamp DNA mini kitä (Qiagen inc.) according to the 
manufacturer’s instructions. Measurements to confirm sufficient DNA concentrations was 
made. The samples were PCR amplified and the PCR product for the different samples 
were then subject to pyrosequencing analysis to measure the mutational status of KRAS 
codon 12, 13 and 61(Richman et al. 2009). The results were described as either mutated-
KRAS regardless of what codon involved or kind of mutation, or as wild-type (normal) 
KRAS.  
3.3.6 Ethical considerations 
The patients were informed about the treatment that was conducted on clinical grounds in 
all patients. The histopathological evaluation was conducted primarily as a part of the 
clinical evaluation but was, in this study reanalyzed in retrospect as was the KRAS 
analysis. The study design was approved by the Ethical review board at the Karolinska 
Institutet.  
3.4 PAPER IV 
3.4.1 Study design 
This study was designed as a retrospective patient series to describe and detect clinical 
factors that could influence how decisions were made when choosing between either 
endoscopic or surgical resection of ampullary adenomatous neoplastic lesions. 
3.4.2 Patients and data collection 
All patients treated with surgical or endoscopic resection, between January 2006 and July 
2018 at the Karolinska University Hospital, for verified or suspected adenomatous 
neoplastic lesions where no invasive, malignant lesion could be identified on cross-
sectional imaging were included. 
A comprehensive list of exclusion criteria was applied to select the small patient group with 
neoplastic ampullary adenomatous lesions that are on the borderline between endoscopic or 
surgical resection, Table 7.  
The patients’ medical journals were reviewed, to obtain data regarding different aspects of 
the initial symptoms, investigations, and findings, leading up to the decision for either 
surgical or endoscopic resection, Table 8. 
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3.4.3 Outcome measures 
Several different measures are of interest when trying to depict and evaluate the decision-
making in this complicated clinical context.  
The final histopathological result after surgical resection was regarded as the final and 
correct diagnosis or if only treated with endoscopic resection, then the histopathological 
result after endoscopic papillectomy was considered as the final diagnosis.  
The final diagnosis was then compared with the initial symptoms, cross-sectional imaging 
results, endoscopic biopsies, post-papillectomy histopathology, treatment decisions made, 
and other findings during the pre-interventional investigations to discern if these findings 
could have aided or altered decision-making when the correct diagnosis was clear after 
resection. Post-interventional complications were also registered, to get a perspective of 
what the clinician chooses between when deciding for either surgery or endoscopy. 
Complications and the grading of severity of complications were done according to Cotton 
et al. (1991) for the EP and Clavien et al. (2009) for the surgical resections. 
3.4.4 Ethical considerations 
The study was performed entirely in retrospect, with no added tests or discomforts for the 
included patients. The data was extracted from the patients’ medical records. The study was 
approved by the Swedish Ethical Review Authority. 
Table 7. Exclusion criteria 
• Neoplasia not originating in the ampulla/papilla on postoperative/post
papillectomy pathology report (e.g. pancreatic cancer, IPMN,
cholangiocarcinoma, duodenal adenoma and adenocarcinoma)
• Non-ampullary adenomatous neoplastic lesion in the duodenum evident at the
time of intended endoscopic resection.
• Clearly invasive malignancy described as such in the original radiology report or
after second opinion from an expert radiologist during multi-disciplinary tumor
board (MDT).
• Patients where the indication for surgery was chronic pancreatitis.
• Familiar adenomatous polyposis or other hereditary polyposis diseases, due to
the special considerations surrounding surveillance and when choosing surgical
resection or not.
• Neuroendocrine tumors (NET)
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Table 8. Definitions of the information extracted from the patient journals 
Definitions Notes 
Patient 
demographics 
Age 
Gender 
Years 
Man / Woman 
Dominant initial 
symptom/finding 
Jaundice 
Pancreatitis 
Bile duct dilatation 
Incidental finding 
Abdominal pain 
Other 
-Clinically evident
-Acute or Chronic
-Asymptomatic, Seen on
imaging
-During endoscopy for other
reasons, e.g., “dysphagia”,
”ulcer control”
-Unspecific, reason for
imaging
e.g., Anemia, GI Bleeding
As reported in the patient 
journal including radiology 
report or the referral 
documentation from other 
hospitals 
Radiological 
findings (CT/MRI) 
Visible non-
invasive lesion? 
Bile duct 
dilatation? 
Main pancreatic 
duct dilatation? 
e.g. “Suspicious lesion”,
“Swollen papilla”, “non-
invasive”
e.g., “Dilated”, “widened”
“Double duct sign”
As written in the original 
radiology report or MDT 
opinion if changed 
Endoscopic 
cell/tissue samples 
Forceps biopsy? 
Brush cytology? 
e.g. “adenoma”, “suspicion
of invasive malignancy”,
“Adenocarcinoma”
Grade of dysplasia?
“Atypic cells”, “Normal 
Cells” “Malignant cells” 
“Unclear”  
As written in the original 
pathology or cytology report 
EUS finding Invasive tumor? 
Non-invasive 
tumor 
Ductal dilatation? 
As stated in the original EUS report 
Treatment decision Multi-disciplinary 
tumor board  
Treatment decision 
Yes/no 
e.g. “malignancy cannot be excluded”, “Ampullary cancer”
“Recommends endoscopic resection “
Endoscopic 
papillectomy 
Curative resection/ 
endoscopically 
cured 
Recurrent disease? 
Complications 
Histopathological 
result 
Complete excision without regard to the number of 
endoscopic sessions required and that the patient was 
adenoma free at two consecutive surveillance endoscopies, 
over a minimum time of 6 months12 
Return of adenoma after being "cured." 
According to consensus criteria39 
See “Forceps biopsy” above 
Surgical resection Histopathological 
result 
Complications 
See “Forceps biopsy” above 
According to Clavien/Dindo40 
EUS – Endoscopic Ultrasonography, MDT- Multi-disciplinary tumor board, CT- Computer Tomography, 
MRI- Magnetic resonance imaging 
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4 RESULTS 
4.1 PAPER I 
Endoscopists from the Nordic countries, nine experts and nine non-experts, responded to 
the two web-based surveys consisting of picture sets showing different papillae taken from 
the proposed classification of the endoscopic appearance of the papilla.  
4.1.1 Interobserver agreement 
In the first survey, the endoscopists were requested to answer what type of papilla, out of 
the four predefined types, that they thought the individual sets of photographs represented. 
The correct answer for each set of photos had been decided by the expert group when they 
created the classification. The endoscopists’ answers were correct, as a group, in 72% 
(range 58%-82%) of the sets of photos, Table 9.  
The interobserver agreement was substantial for the entire group of endoscopists κ =0.62 
(95% CI 0.59-0.66) with comparable results for both experts κ =0.63 and non-experts  
κ =0.61. The level of agreement among the individual endoscopists against the predefined 
classification ranged from moderate κ =0.44 to substantial κ =0.76. 
4.1.2 Intraobserver agreement 
The intraobserver agreement, showed some variation between the individual endoscopists, 
from moderate, κ =0.50, to almost perfect, κ =0.86. The level of intraobserver agreement 
among the endoscopists as a group indicated a substantial agreement κ =0.66 (95%CI 0.59-
0.72). 
The results among experts κ =0.68 (95%CI 0.60–0.76) and non-experts κ =0.62 (95%CI 
0.53–0.72) were again similar. 
4.1.3 Comments 
Both inter- and intraobserver agreement was substantial for the endoscopists as a group, as 
well as for experts and non-experts. Furthermore, as individuals did, the all endoscopists 
have at least a moderate level of agreement or better on both surveys.  
The proposed classification of the endoscopic appearance of the papilla of Vater is 
validated with substantial agreement between both expert and beginner endoscopists.  
Table 9. Inter- and intraobserver agreement. 
Observed 
agreement 
Kappa 
(95% CI) 
Agreement 
Interobserver agreement 
All respondents 0.72 0.62 (0.59-0.66) Substantial 
Expert endoscopists 0.72 0.63 (0.57-0.69) Substantial 
Non-experts endoscopists 0.72 0.61 (0.56-0.67) Substantial 
Intraobserver agreement 
All respondents 0.75 0.66 (0.59-0.72) Substantial 
Expert endoscopists 0.77 0.68 (0.60-0.76) Substantial 
Non-experts endoscopists 0.73 0.62 (0.53-0.72) Substantial 
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4.2 PAPER II 
4.2.1 Patients and distribution of the papilla types 
In total, 1401 patients were included in the study. The mean age of the patients was 66 
years (range 18-101 years), and 52% were female. The most common indications for ERCP 
were common bile duct stones 44%, followed by periampullary tumor and jaundice, see 
Table 10. Classification of the papilla into the predefined types was possible in 98% of the 
patients. In 2% (n=24) of the patients, the endoscopist was unable to select an appropriate 
papilla type. The most common papilla type was regular papilla, Type 1 in 56% of the 
patients, followed by Type 3, protruding, or pendulous papilla occurring in 23%. Small, 
type 2 was seen in 13% and type 4 Creased or Ridged papilla was seen in 8% of the 
patients. 
Table 10. Patient characteristics 
No of patients (n) 1401 
Female 52% 
Age, years, mean (SD) 66 (16) 
Indication for ERCP 
Common bile duct stones 44% 
Periampullary tumor 15% 
Jaundice 13% 
Stricture 9% 
Primary sclerosing cholangitis 7% 
Bile Leak 4% 
Other 8% 
There were no significant differences regarding age, sex, previous cholecystectomy rate, 
NSAID use, use of protective pancreatic stent, or indications for ERCP between the 
different papilla types, except for patients with creased or ridged papilla, Type 4. Compared 
with Type 1 papilla, patients with Type 4 papilla were, on average, younger (mean 59 years 
vs. 66 years, p<0.0001) and had more often primary sclerosing cholangitis as indication for 
ERCP (18.7% vs. 5.7%, p<0.0001). Furthermore, in patients with Type 3 papilla, 
periampullary diverticulum was not as frequent as in Type 1 papilla (6% vs. 13%, 
p=0.001). The level of endoscopist experience was evenly distributed among the different 
papilla types, with only minor, nonsigniﬁcant differences. 
4.2.2  Frequency of difficult cannulation among the papilla types 
The overall frequency of difficult cannulation, regardless of papilla type, was 42% (95% CI 
39-44%). Among the different papilla types, difficult cannulation varied, as shown in
Figure 14. Small papilla, Type 2 (52%, 95% CI 45-59%) and protruding or pendulous
papilla, Type 3 (48%, 95% CI 42-53%) were significantly more often difficult to cannulate
compared to regular, Type 1 papilla (36%, 95% CI 33-40%). There was, accordingly, an
increased odds ratio (OR) for difficult cannulation for both small papilla (OR=1.89, 95% CI
1.37-2.62) and protruding or pendulous Type 3 papilla (OR=1.61, 95%CI 1.24-2.10)
compared with regular, Type 1 papilla. Creased or ridged, Type 4 papilla (43%, 95% CI 34-
52%) did not show any significant difference from regular Type 1 papilla in the frequency
of difficult cannulation.
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Figure 14. Frequency of difficult cannulation distributed between the papilla types. 
4.2.3 Endoscopist experience and difficult cannulation 
An expert endoscopist started the bile duct cannulation in 62% (n=870) of the patients, and 
an endoscopist in the intermediate category started in 17% (n=240). In 291 cases (21%), a 
fellow endoscopist started the cannulation attempts. There was an equal distribution of the 
various levels of endoscopist experience between the different papilla types, with only non-
significant differences.  
Cannulation difficulties were more frequent when endoscopists with less experience 
attempted bile duct cannulation, Table 11. Regardless of papilla type, bile duct cannulation 
was more often difficult when a fellow started (69%, 95% CI 64-74%) as well as when an 
endoscopist from the intermediate category started (49%, 95% CI 42-55%) compared when 
an expert started (30%, 95% CI 27-34%, both p-values <0.0001). Figure 15 also displays 
the frequency of difficult cannulation for endoscopists with varying degrees of experience.  
*Significant difference (p<0.05) compared to Expert, Å non-significant compared to Expert
Table 11. Frequency of difficult cannulation, depending on experience and papilla type 
Experience of the endoscopists 
Papilla type 
Expert Intermediate Fellow 
Type 1, regular papilla 25% 45%* 66%* 
Type 2, small papilla  43% 49%Å 83%* 
Type 3, protruding or pendulous papilla 36% 63%* 69%* 
Type 4, creased or ridged papilla 32% 44%Å 73%* 
Overall 30% 49%*  69%* 
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When only Expert endoscopists performing bile duct cannulation on their own were 
analyzed, the result was similar to that of the entire study population: a significantly higher 
frequency of difficult cannulation when cannulating small papilla, Type 2 (43%, 95% CI 
34-53%, p=0.0002) or protruding or pendulous papilla, Type 3 (36%, 95% CI 29-
43%,p=0,0075) was seen, compared to regular papilla, Type 1 (25%, 95% CI 21-29%).
There was no difference when comparing creased or ridged papilla, Type 4 (32%, 95%CI
21-45%, p=0.22) with Type 1.
Figure 15. Frequency of difficult cannulation between the different papilla types and the experience 
of the endoscopist 
4.2.4 Cannulation technique and papilla type 
There was information about the use of auxiliary cannulation methods recorded in 1355 
patients. In 99% of the ERCPs, the endoscopists began cannulation with guidewire assisted 
cannulation. If cannulation became difficult, 50% of the endoscopists continued with 
guidewire cannulation until cannulation succeeded or failed. Different auxiliary cannulation 
techniques were applied in the remaining patients when cannulation became difficult. 
Standard pre-cut technique as the only auxiliary method was used in 9% of the patients, 
transpancreatic septotomy in 16%, double wire technique in 15%, and a combination of 
transpancreatic septotomy and double guidewire techniques in the remaining 10%. There 
was no significant difference in the choice of auxiliary techniques between the different 
papilla types, Figure 16. 
45 
Figure 16. Auxiliary cannulation techniques used when cannulation became difficult, distributed 
among the different papilla types 
4.2.5 Complications and the papilla types 
The overall post ERCP pancreatitis (PEP) frequency, regardless of papilla type, was 6.7% 
(95%CI 5.5-8.2%). When there was difficult cannulation, the frequency of PEP increased to 
8.9% compared to 5.1% (p=0.006) when cannulation was not difficult. There was also a 
variation in the frequency of PEP between the different papilla types, but none of the 
differences were statistically significant. Regular, Type 1 papilla had a PEP frequency of 
6.1% (95%CI 4.6-8.0%) whereas small, Type 2 papilla had 9.4% (95%CI 5.9-14.6%), 
protruding or pendulous, Type 3 papilla 6.4% (95%CI 4.1-9.7%) and creased or ridged, 
Type 4 had 7.5% (95%CI, 3.6-14.3%). There was an overall low frequency of other 
complications, such as post-interventional bleeding (0.2%) and cholangitis (0.6%), and 
there were no significant differences between the papilla types, Figure 17. 
Figure 17. Frequency of post-ERCP pancreatitis among the different papilla types 
46 
4.2.6 Failed cannulation and the papilla types 
The overall frequency of failed cannulation was low (2.8%, 95% CI 2.1-3.9%), with only 
non-significant differences between the different papilla types. However, the frequency of 
failed cannulation regardless of papilla type increased from 1.9% to 6.3% (p<0.0001) if a 
fellow started cannulation attempts compared to an expert, even though they had to turn the 
endoscope over to a more senior colleague after 5 min. If a fellow started on a small, Type 
2 papilla, there was an overall 14% failed cannulation frequency, compared to 2.7% 
(p=0,018) when an expert performed the cannulation single-handedly. The OR, regardless 
of papilla type, for failed cannulation when a fellow started to cannulate compared to when 
an expert endoscopist started was 4.0 (95% CI, 2.0-8.2, p=0.0001). When a fellow started 
the OR for failed cannulation on a small papilla was 6.1 (95%CI 1.4-27, p=0.017) and on a 
protruding or pendulous papilla 5.2 (95% CI 1.3-21, p=0.022) compared to when an expert 
started. 
4.3 PAPER III 
4.3.1 Procedures and complications 
Between November 2005 and June 2014 were 36 patients treated for verified or suspected 
adenoma in the papilla of Vater with endoscopic papillectomy (EP) at the Karolinska 
University Hospital, Stockholm. Endoscopic biopsies taken before EP showed ampullary 
adenoma in 29 of the patients; in the remaining patients (n=7), resection was due to 
macroscopic suspicion of adenoma. Endoscopic ultrasonography (EUS) was used in 25 
(69%) patients to exclude local signs of invasive growth. Before completion of the 
procedure was a protective pancreatic stent placed in 26 patients (72%).  
Eight patients (22%) had mild to moderate post-procedural complications, two patients 
developed pancreatitis, two with conservatively treated periampullary perforation, two with 
minor post interventional bleeding, and finally two with cholangitis. Obstructive jaundice at 
presentation increased the risk of finding an invasive ampullary adenocarcinoma or a 
concomitant pancreatic adenocarcinoma during endoscopic papillectomy (RR=3.98 CI 95% 
1.46-10.85 p=0.007). Moreover, jaundice at presentation, was associated with an increased 
risk of death due to malignancy during the follow-up period (RR= 3.4 CI 95% 1.2-9.7 
p=0.02). 
4.3.2 Histomorphology  
The development of the histomorphological findings from the endoscopic biopsies to the 
findings in the post papillectomy specimens can be seen in, Figure 18. Among the 29 
patients that had adenoma in the endoscopic biopsies had 28 an adenomatous neoplasia in 
the papillectomy specimens. The grade of dysplasia and invasiveness after assessment of 
the resected specimen differed when compared with the results from the biopsies. Fourteen 
(48%) of the 29 cases with prior endoscopic biopsies, displayed the same histopathological 
grading in the resected specimens after EP. Five patients (17%) with adenoma on biopsies 
had an unknown ampullary adenocarcinoma revealed after EP. No remaining adenomatous 
tissue, only nonspecific inflammation, was the only finding in one patient where biopsies 
prior to EP had shown adenoma with high-grade dysplasia (HGD). Among the seven 
patients without proven neoplasia ahead of EP only two patients did have adenoma while 5 
had non-neoplastic tissue in the post EP resected ampullary specimen; three of them had 
undiagnosed underlying pancreatic cancer. 
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Figure 18. Histopathological development from biopsies to post- endoscopic papillectomy 
Malignant tumors were significantly larger than adenomas (mean 31 mm vs. 14 mm, 
p=0.001), and all adenocarcinomas were greater than 20 mm in diameter. Endoscopic en-
bloc resection was carried out in 22 patients (61%), while a piecemeal technique had to be 
used in the remaining 14 patients. 
4.3.3 KRAS analysis 
Nine, out of the 36 patients, had mutated KRAS shown in the resected specimen. The 
mutations were in codon 12 (n=5), codon 13 (n=2), or codon 61 (n=2). Mutated KRAS was 
found in 4 (80%) of the five patients with ampullary adenocarcinoma and in 4 (20%) of the 
16 adenomas with LGD and in 1 (11%) of 9 with HGD. But the clinical impact was 
difficult to interpret. The clinical outcome for patients who expressed mutated KRAS was 
varied as 4 of the patients with mutated KRAS were cured endoscopically and 5 could not 
be cured endoscopically. The lesions with mutated KRAS tended to be larger than those 
expressing wild-type KRAS (mean 21 mm vs. 14.9 mm, p=n.s). 
4.3.4 Clinical follow-up 
After the index EP, either adenocarcinoma (n=5), adenoma (n=25), or non-neoplastic 
lesions (n=6) were found in the histopathological examination.  
Two of the patients with ampullary malignancy were referred for surgical resection after 
EP, and three continued with further endoscopic follow-up. One patient had only a 
carcinoma in situ tumor and two patients that were considered not fit for surgery. Also, two 
patients with signs of intraductal extension of adenoma and one with concurrent pancreatic 
adenocarcinoma were referred for surgical resection without any further endoscopic follow-
up.  
The remaining 25 patients continued with endoscopic follow-up. During endoscopic 
follow-up, five more patients developed signs of extension of adenoma or malignant 
transformation. Three were sent for surgical resection, and two were treated with palliative 
measures. Unrelated disease or death hit two patients in between follow-up endoscopies, 
and they dropped out of the study.  
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Eighteen (50%) out of 36 patients scheduled for endoscopic papillectomy were 
endoscopically cured after a mean follow-up time of 47 months (range 16-92). Among the 
patients with confirmed adenoma after EP were 16 (73%) endoscopically cured. 
Eradication of adenomatous tissue required only one endoscopic resection in 11 cases 
(61%), the seven remaining patients required between 2 and 7 sessions to be cleared of all 
adenomatous tissue. One patient with ampullary adenocarcinoma who was not fit for 
surgery was treated seven times with endoscopic procedures to clear all adenomatous 
tissue; she was recurrence-free at the end of follow-up and is still alive, eleven years after 
the endoscopic papillectomy. 
4.4 PAPER IV 
4.4.1 Patients 
During the study period from January 2006 to July 2018 was 1426 patients treated with 
either surgical or endoscopically resection for presumed or verified periampullary tumor at 
the Karolinska University Hospital. 172 patients fulfilled the inclusion criteria, while the 
remaining (n=1254) were excluded on various grounds, Table 12. 
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Table 12. List of excluded patients 
Exclusion criteria n 
Non-ampullary neoplastic lesions 1004 
Pancreatic cancer 639 
Duodenal neoplastic lesions 102 
Cholangiocarcinoma 56 
Neuroendocrine tumor 67 
IPMN or pancreatic cystic tumors 140 
Invasive ampullary adenocarcinoma on imaging 85 
Familiar adenomatous polyposis 52 
Miscellaneous indications (e.g. metastasis, chronic pancreatitis) 111 
Missing Data 2 
Total 1254 
In the study population, there was an equal gender distribution (women n=86, male n=86) 
with a mean age of 66 years (range 33-85). Abdominal pain was more frequent as the 
dominating symptom among women than among men (22% vs. 6%, p=0.004), while 
jaundice was more frequent among men (29% vs. 49%, p=0.01).  
Jaundice at presentation was more common in patients with adenocarcinoma, as the final 
diagnosis than among patients with adenoma (65% vs. 9%, p<0.0001). Among the patients 
with adenoma as the final diagnosis were abdominal pain a frequent initial symptom (20%), 
as well as previous, or recurrent pancreatitis (14%). In 27% of the patients with adenoma as 
the final diagnosis were the lesion discovered incidentally during upper gastrointestinal 
endoscopy for other reasons. 
4.4.2 Cross-sectional imaging 
All patients were examined with CT (n=164), both CT and MRI (n=39), or only MRI (n=8), 
at some time-point during the pre-interventional investigations. 
In 45 patients there was a suspicion of a lesion in the ampullary area mentioned in the 
radiology report, but no apparent signs of an invasive, malignant, lesion. The suspicion of a 
lesion, was in this narrowly selected patient group, not more common if the final diagnosis 
were adenocarcinoma compared to if it was a benign diagnosis (31% vs. 21%, p=0.12). 
Bile duct dilation was seen in 140 patients (81%) and pancreatic ductal dilation was seen in 
79 (46%) of the patients. Both ducts were dilated in 75 patients (45%), the so-called 
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“double duct sign”. Double duct sign was more frequent among patients with 
adenocarcinoma compared to when they had adenoma as the final diagnosis (60% vs. 26%, 
p<0.0001). All patients with adenocarcinoma (n=82) had dilated bile ducts.  
4.4.3 The final histopathological diagnosis  
The final diagnoses in the entire study population was that 48% (n=82) had ampullary 
adenocarcinoma (AA), 15% (n=25), adenoma with high-grade dysplasia (HGD), 24% 
(n=41), adenoma with low-grade dysplasia (LGD) and, 14% (n=24) with non-neoplastic 
lesions. The non-neoplastic lesions consisted of findings such as unspecific inflammation, 
with or without pancreatitis, fibrosis of the papilla, gallstone disease, or periampullary 
diverticulum. 
4.4.4 Endoscopic biopsies and brush cytology 
Endoscopic biopsies were taken before deciding on EP or surgical resection in 80% 
(n=137) of the patients. The overall concordance between endoscopic biopsies and the final 
diagnosis is displayed in Table 13. 
The sensitivity for endoscopic biopsies to correctly diagnose adenocarcinoma was 58% 
(95% CI, 45-70%) with a specificity of 97% (95 CI, 90-100%), and the diagnostic accuracy 
was 79% with a positive predictive value 95% (95% CI, 82-99%). In patients where 
endoscopic biopsies had shown adenoma had 94% (n=77 out of 82) a neoplastic lesion of 
some kind as the final diagnosis. Adenocarcinoma was revealed in 27% (n=22) of the 
patients with adenoma on the endoscopic biopsies. 
Table 13. Endoscopic biopsies and the histopathological final diagnosis 
Endoscopic biopsies 
Final histopathological diagnosis 
Adenocarcinoma Adenoma 
HGD 
Adenoma 
LGD 
Non-Neoplastic SUM 
Adenocarcinoma 37 1 1 22 
Adenoma HGD 11 13 2 3 29 
Adenoma LGD 11 10 30 2 53 
Non-neoplasic lesion 5 1 10 16 
SUM 64 24 33 16 137 
Brush cytology was taken during ERCP in 69 of the patients. Eight patients had malignant 
cells or atypia with suspicion of malignancy written in the cytology report. Six out of these 
had adenocarcinoma as the final diagnosis. The sensitivity in diagnosing malignancy was 
25% (95%CI 10%-47%), and the specificity was 96% (95% CI 85%-100%). If also 
including patients with unspecific atypia in the brush cytology as a sign of malignancy, then 
the sensitivity became 54% and the specificity 64%. Therefore, when finding malignant 
cells on brush cytology, the cancer diagnosis is most likely correct, however an uncertain 
finding, with lower grades of atypia, gave no decisive information in this patient group.  
4.4.5 EUS and final diagnosis 
At the beginning of the study-period was EUS not often used at our hospital but has over 
the years been implemented more regularly. In Sweden, EUS is still under development and 
has not been implemented outside expert centers. EUS was performed on 36% (n=62) out 
of all the patients (n=172) and in many instances before EP (n=26), or at the same 
endoscopic session as the EP (n=17). The results from the EUS examinations were, 48% 
(n=30) in agreement with the patients’ final diagnosis. In 34% (n=21) of the patients did the 
EUS examination under-stage the lesion, and in 4 patients were the lesions over-staged. 
Seven patients had an inconclusive examination due to technical problems. If the EUS 
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examiner stated that the patient had a malignant lesion (n=3), this was, in all cases, correct 
compared with the final diagnosis.  
4.4.6 Endoscopic papillectomy (EP) 
Endoscopic papillectomy (EP) was the initial treatment for 76 patients, see Figure 19. 
Endoscopic biopsies were in 82% (n=62) of the patients taken before EP. In 14 patients no 
biopsies were taken before EP, instead was the ampullary lesion discovered incidentally 
during a clinically indicated ERCP and the EP performed at the discretion of the 
endoscopist. Adenoma on biopsies, with various degrees of dysplasia, was the indication 
for the EP in 78% (n=59) of the patients. Three patients had biopsies with only non-
neoplastic findings prior to EP, and all three did not have any signs of neoplasia after EP 
either. 
4.4.6.1 Endoscopic papillectomy and the final diagnosis 
The 76 patients resected with EP had in 89% (n=68) an adenomatous neoplastic lesion as 
the final diagnosis. For those who had an adenomatous neoplastic lesion as the final 
diagnosis was EP curative for 59% (n=40), Figure 19. The final diagnosis among the 
endoscopically cured were adenoma with LGD in 83% (n=33), adenoma with HGD in 15% 
(n=6), and one patient had a small adenocarcinoma with no sign of recurrence during long-
term follow-up. 
Eight patients had a non-neoplastic final diagnosis even though 4 of them had biopsies 
showing adenoma. One patient with non-neoplastic findings at EP had clinical suspicion of 
neoplasia and underwent surgical resection.  
Twenty-one (28%), out of the 76 patients treated with EP, were referred for surgical 
resection due to either adenocarcinoma (n=8) on post-EP histopathology or adenoma with 
signs of intraductal extension (n=13). Additionally, six patients treated with EP had 
malignancy or advanced adenoma discovered at EP. They were not fit for surgery, and 
therefore treated with palliative measures.  
4.4.6.2 Endoscopic papillectomy among patient with biopsy-proven adenoma 
Of the 59 patients with biopsy-proven adenoma prior to EP, was 58% (n=34) cured of the 
neoplastic lesions with endoscopic resection. In 7% (n=4) of the patients, there were only 
non-neoplastic findings, diagnosed after EP, with no signs of residual adenoma. 
Adenocarcinoma was revealed in 14% (n=8) of the patients where biopsies had shown 
adenoma, while 47 patients still had adenoma in the post EP tissue samples.  
4.4.6.3 Complications after endoscopic papillectomy 
The 76 patients treated with EP had in 79% (n=60) an uneventful intervention and were in 
most cases, sent home the day after the intervention. However, in 21% (n=16) of the 
patients, a post-EP complication occurred. The most severe complication was one patient 
who died 111 days post-EP due to severe post-procedural pancreatitis. The patient was 
examined with other invasive endoscopic techniques such as per-oral pancreatoscopy and 
EUS with biopsies, during the same endoscopic intervention as the EP, due to suspicion of 
a pancreatic lesion that could not be verified. Two patients with perforation were treated 
successfully with conservative measures and could be sent home on day 6, respectively day 
9 postoperatively. The most common complications after EP were bleeding (8%), that 
needed transfusions or endoscopic intervention, and pancreatitis (7%), which were mild and 
self-limiting in many cases. One patient with pancreatitis developed multi-organ failure but 
recovered and one patient with severe bleeding needed to be treated with angiography and 
coiling. 
One of the patients treated with surgical resection after not being cured with EP had a mild 
self-limiting pancreatitis after the EP that did not delay surgery. 
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Figure 19. Clinical and histopathological development for patients treated with endoscopic papillectomy 
4.4.7 Surgical resection 
A multidisciplinary tumor board (MDT) evaluated the preinterventional investigations and 
made the treatment decisions for all patients treated with surgical resection (n=117), the 
majority of whom were treated with PDE (n=113). Three patients were operated with pancreas-
preserving duodenectomy, and one patient had a transduodenal ampullectomy. The results from 
these four patients are included in the surgical resection group.  
The decision to choose surgical resection were based on only imaging and no biopsies in 21 
patients. The majority (n=75) had endoscopic examination with biopsies together with imaging 
as the basis for deciding for surgery and 21 patients were surgically resected after EP, Figure 
20.
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Figure 20. Histological development among the surgically resected patients 
4.4.7.1 Surgical resection after endoscopic examination with biopsies. 
In all the patients with endoscopic biopsies (n=75) taken prior to surgical resection did 73% 
(n=55) have adenocarcinoma, 12% (n=9) adenoma with HGD, 4% (n=3) adenoma with 
LGD and 11% (n=8) had non-neoplastic findings as their final diagnosis. 
Among the 37 patients that had adenocarcinoma or adenoma with suspected invasive 
adenocarcinoma on biopsies, all had ampullary adenocarcinoma as the final diagnosis.  
Additionally, 25 patients were surgically operated, where endoscopic biopsies had shown 
either, adenoma with HGD (n=15), or adenoma with LGD (n=10). In this group had 52% 
(n=13) adenocarcinoma, and 12 still had adenoma while 1 had only a non-neoplastic lesion. 
Finally, among the patients were biopsies could not confirm neoplasia (n=13) had five 
patients ampullary adenocarcinoma, one adenoma with HGD and seven patients (54%) still 
had non-neoplastic lesions after surgery.  
4.4.7.2 Surgical resection without endoscopic biopsies 
Among the 21 patients that were surgically resected, without prior endoscopic biopsies had 
52% (n=11) ampullary adenocarcinoma as their final diagnosis. However, 38% (n=8) had 
non-neoplastic findings, and 10% (n=2) had small adenomas (3-4 mm) with LGD 
combined with suspected gallstone disease, as the final diagnoses after surgery. 
4.4.7.3 Surgical resection after endoscopic papillectomy 
Twenty-one patients were operated with PDE after EP. Seven out of the eight patients with 
adenocarcinoma after EP, had adenocarcinoma as well in the final surgically resected 
specimen; one had only residual adenoma with HGD. 
The 13 patients with intra-ductal extension of adenoma had in 5 patients invasive 
adenocarcinoma, while seven still had adenomas with intra-ductal invasion. One had on 
signs of remaining neoplastic tissue in the postoperative histopathology.  
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4.4.7.4 Complications after surgical resection 
Pancreatic surgery is a major surgical resection and as such, have a high frequency of 
postoperative morbidity. In this study, 67% (n=78) of the surgically resected patients 
(n=117) had postoperative complications, that were in 34% (n=40) of the patients mild and 
not requiring any advanced interventions (Clavien 1-2). 
Two (1.7%) patients died due to postoperative complications (Clavien 5), and 7,5% (n=9) 
of the patients needed treatment in the intensive care unit for multi- or single organ failure 
(Clavien 4a and b). The remaining 23% (n=27) had an intermediate degree of complications 
(Clavien 3a and b), that were treated with endoscopic, surgical, or radiologic interventions 
to drain collections, stop bleedings, reoperation with rescue pancreatectomy, or ductal 
drainage due to anastomotic leakage. 
Operated patients with adenocarcinoma as their final diagnosis had significant 
complications (Clavien 3a-5) in 27% (n=21/78), and patients with benign final diagnosis 
had in 45% (n=17/38) significant complications, but the difference was not statistically 
significant (p=0.09). 
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5 DISCUSSION 
This thesis focuses on a few issues concerning the papilla of Vater, or major duodenal 
papilla. The attention has been on two different clinical problems. First, in Paper I and 
Paper II the focus is on the endoscopic appearance of the papilla and to answer the 
question, if the appearance of the papilla influences transpapillary cannulation during 
ERCP.  
Paper III and Paper IV deal with various aspects surrounding the clinical management of 
early ampullary neoplastic tumors in the papilla of Vater.  
Paper III shows that endoscopic papillectomy is a safe and potentially curative treatment 
possibility for early neoplastic lesions in the papilla of Vater. While Paper IV sheds light 
upon the various difficulties surrounding clinical management of early ampullary neoplastic 
lesions in the papilla of Vater. We are evaluating decision-making and investigations prior 
to curative, either endoscopic or surgical, resection.  
5.1 THE ENDOSCOPIC APPEARANCE AND BILE DUCT CANNULATION 
 In this thesis is an inter- and intraobserver validated classification of the endoscopic 
appearance of the papilla of Vater presented. Furthermore, the proposed classification is put 
to the test, measuring circumstances surrounding bile duct cannulation and especially the 
frequency of difficult cannulation, to evaluate its clinical use. 
5.1.1 Interobserver agreement in classification studies been proven to 
To evaluate a diagnostic or clinical method that involves subjective interpretation, there 
must be an evaluation of the degree of agreement between the different interpreters to make 
the method valid. There have been several studies performed evaluating various aspects of 
image interpretation in the field of gastrointestinal endoscopy (Armstrong et al.1996; 
Asfeldt et al. 2009; Silva et al. 2011; Hirano et al. 2013). In Paper I, concerning the 
endoscopic classification of the macroscopic appearance of the papilla of Vater, there is a 
substantial agreement among endoscopists of different degrees of experience and the 
predefined classification. The level of agreement is at a similar level to other studies in the 
field of endoscopic image interpretation, used in in clinical practice today, such as the LA 
classification concerning the degree of reflux esophagitis (Lundell et al. 1999). The 
proposed classification of the endoscopic appearance of the papilla of Vater is the only 
classification of the endoscopic appearance of the papilla that has undergone any 
interobserver agreement evaluation by multiple observers and from several centers.  
In our papilla image study, we choose to use endoscopic images for the intra- and 
interobserver evaluation. It can be argued, however, that the use of endoscopic video 
sequences could have been better than using endoscopic images when performing this kind 
of validation studies. There are some reports have used video sequences (Bendtsen et al. 
1990) in a similar setting like this and others that have used still images (Curvers et al. 
2008) instead. No comparison between the different methods have been made, and 
photographic images are still the standard way of documenting endoscopic findings.  
5.1.2 The endoscopic appearance and difficult cannulation 
The endoscopic appearance of the papilla of Vater has consistently been claimed to 
influence bile duct cannulation during ERCP (Lee et al. 2014b; Testoni et al. 2016; Berry et 
al. 2019). Earlier statements about cannulation difficulties and endoscopic appearance have 
concluded, without any clear definition, that small and protruding papilla are more often 
difficult to cannulate and therefore also have a higher risk for PEP (Swan et al. 2011; 
Katsinelos et al. 2012; Bakman and Freeman 2013). Not until the present study has the 
influence of the different appearances of the papilla on bile duct cannulation been 
quantified, and prospectively determined. With the use of the validated classification of the 
endoscopic appearance and the definition promoted by the ESGE for difficult cannulation, 
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we have shown that cannulation is more frequently difficult for Type 2, Small papillae and 
Type 3, Protruding or Pendulous papillae than for Type 1, Regular papilla, Figure 13.  
The overall frequency of difficult cannulation, in the present study, regardless of papilla 
type, was 42% using the 5-5-2 definition and this is on par with what Ismael et al (2019) 
have found. In their patient series they had 37.9 % frequency of difficult cannulation when 
consecutively measuring bile duct cannulation using the 5-5-2 definition in an everyday 
clinical setting. Their results also confirm that there is a higher frequency of PEP if the 
cannulation becomes difficult compared to when it is easy (2.2% vs. 7.1%, p=0.001). 
Watanabe et al. (2019) constructed a classification of the endoscopic appearance where 
three expert endoscopists classified endoscopic pictures into the different papilla types and 
reviewed cannulation data in retrospect. They suggested two different aspects of the 
endoscopic appearance for their classification; first the amount of supra-papillary 
protrusion of the intraduodenal portion of the ducts, separated into three different grades; 
second five different surface patterns of the papilla itself. Watanabe et al. decided on five 
attempts as their definition of difficult cannulation with no time-limit. With their definition 
of difficult cannulation, they had an overall frequency of difficult cannulation of 41.8%. 
They concluded that the papilla type of Papilla-L (Large protrusion) had a higher OR for 
difficult cannulation compared to the average level of difficult cannulation, but if this 
applied to all the different surface patterns was not clear.  
The classification constructed by Watanabe et al. (2019) is complicated, with 3x5 potential 
types of papillae, and all the patients were classified in retrospect by three senior 
endoscopists.   
When a new classification is constructed, there must be a compromise between usefulness 
and precision. Our classification, based on four different types, is inter-observer validated 
among both experts and beginner endoscopists, to a similar degree, making the 
classification recognizable, easy to use and to generalize. The classification could have 
been more elaborate, including several subclasses of papillae, but then it would have been 
more difficult to use in the daily clinical praxis.   
5.1.3 Endoscopic appearance and cannulation technique 
In earlier studies, where the influence of the endoscopic appearance were discussed, has the 
focus been the variation in the degree of supra-papillary protrusion, and how that influences 
when choosing pre-cut technique, see section 1.5.  
Wen et al. (2018) compared the transpancreatic septotomy technique against needle-knife 
fistulotomy technique where the choice of technique was dependent on the morphology of 
the papilla. They separated the papillae into either “small”, with no supra-papillary 
protrusion, or a “protuberant” papilla, with a visible supra-papillary bulge. Transpancreatic 
septotomy was the preferred technique used when the papilla was “small” and a guidewire 
had been placed in the pancreatic duct, otherwise was the needle-knife fistulotomy 
technique be used. However, they could not show any differences between the two 
techniques on cannulation success or complications. Their study was retrospective and with 
a major difference in the number of patients in the two treatment arms. The “small” papilla 
group had three times as many subjects as the protruding type group. Probably are the 
“small” papillae in Wen et al comparable to Type 1, 2 and 4 in our proposed classification. 
In our data, there was no indication that the endoscopists had any preference for a specific 
type of auxiliary cannulation technique, depending on the endoscopic appearance. Several 
previous studies have argued that needle-knife fistulotomy technique is the preferred 
technique when the papilla is similar to the Type 3, Protruding or Pendulous type, thereby 
also avoiding the papillary orifice and perhaps even have a lower frequency of PEP 
(Mavrogiannis et al. 1999). 
Perhaps can future studies focusing on the cannulation techniques used when cannulating 
the different types of papillae shed some light on these questions.  
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5.1.4 Consequences for training in ERCP 
In the present study we found that the experience of the endoscopist influenced the 
frequency of difficult cannulation for all the papilla types. That experience influences bile 
duct cannulation is not a surprising finding, but it has previously not been quantified using 
the ESGE promoted definition (5-5-2) and it is one of the few prospective studies that have 
the frequency of difficult cannulation as the primary endpoint. Because difficult 
cannulation is one of the acknowledged risk factors for PEP (Dumonceau et al. 2014), the 
question regarding the high frequency of difficult cannulation among beginners learning 
ERCP has to be addressed. The aim of our study was not primarily to investigate the PEP 
frequency, but the influence the different papilla types have on bile duct cannulation. The 
possibility of an increased risk for PEP when a trainee is making the initial attempts at 
cannulation has been discussed previously. Some report an increased risk for PEP (Cheng 
et al. 2006) while others have not seen any increase in the risk for PEP (Elmunzer et al. 
2012; Lua et al. 2015; Leerhøy et al. 2016) 
Lee et al (2019a) in a very recent study from South Korea measured post ERCP 
complications among patients undergoing ERCP with a naïve papilla, and recorded the 
level of experience among the endoscopists. They report that the least experienced (<200 
lifetime ERCPs) endoscopists have a higher frequency of PEP (12% vs 6.8%) compared 
with more experienced endoscopists. In that study, they defined difficult cannulation as any 
of the criteria, >10 attempts, one guidewire passage into the MPD, or >5 minutes. Using 
this definition, they could show a clear difference between experts and less experienced in 
the frequency of difficult cannulation (49.7% vs 37.3%, p<0.001). At multivariate analysis, 
taking the frequency of difficult cannulation into the analysis, they showed a higher OR for 
PEP among inexperienced endoscopists, OR 1.63 (95%CI 1.05-2.53).  
The higher frequency of difficult cannulation among inexperienced endoscopists were an 
expected finding, but in what way does the higher frequency of difficult cannulation among 
beginners influences the risk of PEP. Future studies with a clear definition of trainee 
participation measuring the cannulation process and complicationsmight answer the 
question. 
Failure to cannulate occurred more frequently if a fellow (<200 lifetime ERCPs) started 
cannulation attempts, even though a more senior colleague took over cannulation after 5 
minutes, compared to when an expert performed cannulation on their own. The higher 
failure frequency was especially noticeable when a fellow was faced with a Type 2, small 
papilla. This finding, if confirmed, must have consequences on how future training in 
ERCP is conducted. It may suggest that if a fellow sees a small, Type 2 or perhaps even a 
protruding or pendulous, Type 3 papilla, they probably should withhold from cannulation 
attempts, not to jeopardize further cannulation success. 
In previous reports, there are conflicting conclusions concerning these matters, where some 
studies indicate a higher cannulation failure rate (Williams et al. 2012; Peng et al. 2013) 
while others have found no difference (Voiosu et al. 2019) or some even showed better 
procedural success with trainee participation (Ekkelenkamp et al. 2015). There is no 
universal definition for “trainee participation” among the different studies, and with 
conflicting results, the question is still unanswered.  
5.1.5 Difficult cannulation frequency as a measure of proficiency 
The self-evident finding that the frequency of difficult cannulation is lower among experts 
than among beginners might be used when evaluating education or monitored as a quality 
measure. The frequency of successful cannulation of the desired duct is the most frequently 
used intraprocedural quality measure (Domagk et al, 2018; Adler et al, 2015), where the 
goal is >98% cannulation success or at least above 80-85% to been regarded as having 
completed basic training. Failed cannulation is of course an important variable, but it does 
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not measure the ability of the endoscopist in all the ERCPs where cannulation succeeds. In 
addition, by measuring the rate of difficult cannulation, is the entire process of cannulation 
also evaluated, with a variable that has a clear correlation to PEP frequency (Ismail et al. 
2019). The added benefit could also be that keeping track of both cannulation time and 
attempts could help in making a timely shift to auxiliary cannulation techniques, as 
proposed in several meta-analyses (Sundaralingam et al. 2015; Chen et al. 2018; Tang et al. 
2018).  
Further studies about the use of difficult cannulation frequency as a quality measure, might 
determine a benchmark for what frequency of difficult cannulation one should achieve and 
maintain to be considered a qualified ERCP endoscopist. 
5.2 ENDOSCOPIC PAPILLECTOMY 
Endoscopic papillectomy (EP) has, since the beginning of the study period in 2005, been 
proven to be a safe and effective first-line treatment when resecting adenomas in the 
ampullary region in several studies and guidelines (Chathadi et al. 2015). With the 
improvements in cross-sectional image diagnostics and the increasing availability of 
endoscopic examinations it is likely that discovering asymptomatic, suspicious lesions in 
the ampullary region suitable for endoscopic resection will increase.  
Although EP is a comparatively lenient treatment if all goes well, there are potentially 
disastrous complications if not performed with care and with a great deal of experience in 
complex endoscopic procedures.  
5.2.1 Clinical outcome after Endoscopic papillectomy 
Both Paper III and Paper IV shows that EP is a useful intervention with curative potential 
for patients with ampullary adenomas. If EP cannot offer a curative resection it can serve as 
a macro biopsy to aid in decision-making prior to surgery.  
Among the patients scheduled for EP was 50-59% of the patients in our studies cured with 
the endoscopic resection. In a recent meta-analysis, they concluded that the overall curative 
resection frequency was 87.1%, with recurrence in 11.8% of the patients (Spadaccini et al. 
2019). In this meta-analysis, they also conclude that it is difficult to compare the 
oncological results between patient series, because the indications for EP, the investigations 
leading up to EP and the definition of treatment success is not standardized between the 
different patient series. It is therefore difficult to put our results into perspective, but our 
frequency of curative resections is on the lower end of what other studies have presented 
(Laleman et al. 2013; Klein et al. 2018), Table 4 . One could guess that the reasons for the 
relatively low curative rate in our studies is that surgeons performing these resections are, 
perhaps, presented to a different case-mix, and maybe a lower threshold to turn to surgical 
resection. 
There are several factors, in our data, that influenced treatment success. The size of the 
lesion (>20 mm) as well as jaundice at diagnosis increased the likelihood of finding an 
undiagnosed malignancy after EP. The size of the lesion as a risk factor for malignancy is 
emphasized in several reports (Patel et al. 2016; Kandler and Neuhaus 2018). 
5.2.2 Complications after endoscopic papillectomy 
There is a high post-interventional complication frequency after EP compared with other 
endoscopic interventions. The complications are mild to moderate in most patients, and 
with the same kinds of complications that occur after ERCP, but with a slightly higher 
frequency. In a recent meta-analysis, including, 1751 patients Spadaccini et al. (2019) 
report a 24.9% overall complication frequency, with pancreatitis in 11.9% and bleeding in 
10.6% of the patients. Perforations were at 2.7%, which is considerably higher than in 
ordinary ERCP patients (0.1-0.6%) (Andersson et al. 2012). 
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In our studies, the complication frequencies were at 21% and 22% or the patients, 
respectively.  
5.3 CLINICAL MANAGEMENT OF AMPULLARY NEOPLASTIC LESIONS 
5.3.1 Early symptoms of an ampullary lesion 
Among the patients included in Paper IV were obstructive jaundice (39%) the most 
frequent symptom at presentation, followed by unspecific bile duct dilatation (15%). Irani 
et al., (2009) in their study on endoscopic papillectomy, had 48% (72 out of 150) of the 
patients cholestasis as the initial symptom. In a recent study, by (Li et al. 2019b) the 
frequency of jaundice at presentation was significantly higher for patients with 
adenocarcinoma compared to patients with adenoma as the final diagnosis (47.8% vs 
13.8%. p=0.001) as was also the frequency of bile duct dilatation (34.8% vs. 9,2%, 
p=0.001). Ridtitid et al. (2014) concluded that jaundice at presentation was more common 
in patients with incomplete EP.  
Jaundice at presentation was also in our data linked to a higher frequency of 
adenocarcinoma, compared to the patients that had adenoma as the final diagnosis (65% vs. 
9%, p<0.0001). Probably are the patients without jaundice at presentation the once where 
EP has the best chance to offer a curative resection. Abdominal pain as the initial symptom 
or an incidental finding of an ampullary lesion might also indicate a benign disease (Irani et 
al. 2009). Sahar et al. (2019) reported that in their patient series had 72% of the patients 
with adenomas no symptoms prior to diagnosis and only 8% of the patients had jaundice or 
biliary obstruction.  
Although ampullary neoplastic tumors are rare lesions among patients with abdominal pain, 
it is a differential diagnosis to have in mind, especially when performing upper 
gastrointestinal endoscopy or in patients with biliary type of pain.  
5.3.2 Imaging and ampullary neoplastic lesions 
The investigational methods used in the preoperative evaluation of a suspected ampullary 
neoplastic lesion are duodenoscopy with biopsies, ERCP, EUS, IDUS, MDCT, and MRI 
with MRCP. All have their strengths and weaknesses in confirming the correct diagnosis. 
IDUS is the most accurate investigational method for local staging of ampullary lesions but 
it is technically complex, invasive, and has few other investigational applications, making it 
rarely used in clinical praxis (Ito et al. 2007).  
5.3.2.1 Pre-interventional imaging 
MDCT is widely used in many different clinical situations and is good at finding indirect 
signs of suspected ampullary lesions such as dilated ducts and protrusion of the papilla, as 
well as evaluating the presence of distant metastasis (Nikolaidis et al. 2014).  
In our data we excluded patients with a clearly invasive lesion, seen on imaging. The 
frequency, in our data, of patients where imaging showed a suspected, non-invasive lesion 
was similar regardless whether the final diagnosis was adenoma or adenocarcinoma. In a 
recent study by Angthong et al., (2018) had 41.9% of the patient with confirmed ampullary 
adenocarcinoma no visible ampullary mass that could be seen on MDCT. These findings 
implicate that MDCT has no, or at best moderate, ability to differentiate malignant from 
benign ampullary lesion (Lee et al. 2011b). Zbar et al. (2012) report that MDCT have a 
sensitivity between 19% to 67% in correctly diagnosing the T-stage of an ampullary lesion. 
Chen et al (2009) report that MRI has an accuracy 54% in correctly diagnosing the T-stage. 
In both of our studies the exact T-stage of the lesions was not possible to evaluate from the 
retrospective analysis of the EUS reports. The endoscopist only stated if the lesions were 
invasive, malignant or suitable for endoscopic resection. The quality of the EUS 
examinations varied a lot during the study period at our hospital and should be 
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implemented more often in this patient group. In published studies has EUS a high accuracy 
(63-90%) to correctly evaluate the T-stage of an ampullary lesion (Ito et al. 2010; Okano et 
al. 2013) and is better than MRI and MDCT.  
To evaluate the amount of intraductal extension and not T-stage has ERCP similar accuracy 
as EUS according to Ridtitid et al. (2015). Both methods have a sensitivity of 80% or more 
and a specificity of 93% to determine intraductal extension correctly when comparing with 
the final result after surgery. 
To determine the N-stage of the lesion is probably MRI better than EUS but there is only 
one study directly comparing these modalities (Chen et al 2009) 
5.3.2.2 Ductal dilatation and final diagnosis 
The finding of dilated pancreatobiliary ducts, double duct sign, on imaging is an ominous 
sign for a malignant disease in the periampullary region. Sinha et al. (2015) showed in a 
retrospective study on MRCP investigations, where 81 patients with double duct sign were 
evaluated to determine the underlying reason for the ductal dilation, that the most common 
reason for double duct sign was choledochal stones. They also report that the patients with 
jaundice and double duct sign had 48% a malignant disease. In our data were the double 
duct sign significantly more frequent among patients with malignant disease than among 
those with a benign final diagnosis (60% vs 26%, p<0.0001).  
Among patients with an unclear bile duct dilation are the underlying explanations for the 
bile duct dilation in many instances not found. Smith et al (2015) conducted a systematic 
review of the currently available studies on dilated bile ducts and concluded that the data is 
insufficient to make any clear recommendations about how to handle patients with 
unexplained bile duct dilation. However, they also conclude that a small fraction of the 
patients, preferably the ones with symptoms or raised liver function tests, must be further 
evaluated, as a fraction of them have an underlying malignant diagnosis.  
When evaluating 68 patients with double duct sign without jaundice and no visible lesion 
on MDCT with EUS, had 42 of the patients no detectable reason for the dilation. Six of the 
patients had a periampullary neoplasia that had not been seen on MDCT (Cohen et al. 
2014).  
The dilation of the pancreatic duct is a more worrisome sign than the dilation of the bile 
duct, especially when there is a pancreatic lesion responsible (Oppong et al. 2014; Chiaro et 
al. 2019). In Del Chiaro et al. (2019), the main pancreatic duct dilatation was the only 
variable associated with an increased probability of underlying malignancy or HGD when 
evaluating intraductal papillary mucinous neoplasms (IPMN) of the pancreas. 
5.3.3 Endoscopic biopsies in ampullary neoplasia 
Evaluating endoscopic biopsies is not easy. In paper III the endoscopic biopsies were in 
concordance with the post-EP resected specimen in only 48% of the patients, and in paper 
IV the endoscopic biopsies were in concordance with the final diagnosis in 66% of the 
patients. The reason for the higher concordance in paper IV is probably because of the 
higher frequency of patients in paper IV with adenocarcinoma as the final diagnosis. In 
paper IV the sensitivity was 58% (95% CI, 45-70%) and the specificity was 97% (95% CI, 
90-100%) for endoscopic biopsies to correctly diagnose adenocarcinoma and it is similar to
what other studies previously have shown (Elek et al. 2003).
One other important aspect of endoscopic biopsies is that if biopsies show adenoma then
there is nearly always adenoma or adenocarcinoma in the final diagnosis. This results
indicates that biopsies showing adenoma must lead, at least, to further investigations and
deciding upon resectional therapy.
Lee et al. (2014a) tried to both take the endoscopic appearance of the papilla and the results
from the biopsies and combine those to guide in decision-making. They concluded that
biopsies and the visual impression of the papilla was equally important, and that biopsies
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had a tendency to under-stage the lesions and the visual impression tended to over-stage the 
lesions. 
A way to improve tissue diagnosis from endoscopic biopsies might be to analyze the DNA 
content, as shown by Wen et al (2019). They concluded that tissue samples from 
endoscopic biopsies presenting abnormal DNA content were more common in biopsies 
showing HGD. In patients were biopsies showed a non-dysplastic mucosa there were no 
abnormal DNA. Even more interesting was that they found that in the small group of 
patients with LGD on histopatological examination and abnormal DNA content developed 
86% HGD or adenocarcinoma within 2 years. Those with normal DNA content and LGD 
developed HGD or adenocarcinoma in 10% of the patients within 7 years. These findings 
must be repeated in a larger study to evaluate the clinical use of the method.  
5.3.4 Importance of KRAS mutational status 
Earlier studies have reported a varied expression of mutated KRAS in surgical specimens 
from ampullary adenocarcinomas and that the presence of mutated KRAS influences long 
term prognosis (Mafficini et al. 2018). The frequency of mutated KRAS also seems to be 
more common in the pancreatobiliary subtype (Perkins et al. 2019). Our study is the first to 
investigate the presence of mutated KRAS in tissue of endoscopically resected specimen 
collected at papillectomy. Mutated KRAS was present in 80% of the ampullary 
adenocarcinomas, but it was also present in several (25%) of the adenomas with low-grade 
dysplasia, making it hard to draw any conclusions on the long-term prognosis in these 
patient groups.  
Exploration of biomarkers that can be analyzed from endoscopic biopsies or cytology 
specimen is clinically relevant, and one of the investigated candidates is mutated KRAS 
(Kipp et al. 2010; Layfield et al. 2014). Perhaps, with DNA analysis and molecular 
profiling can future generations of oncological treatment be tailored from small biopsies or 
even cytology (Dreyer et al. 2019). 
5.4 ENDOSCOPIC PAPILLECTOMY OR SURGICAL RESECTION 
5.4.1 Can patients with adenocarcinoma be endoscopically cured? 
The recommendation that patients with a malignant ampullary tumor should be referred to 
curative surgical resection has been challenged over the years (Pérez-Cuadrado-Robles et 
al. 2018). It has previously been concluded, from studies on the surgically resected 
specimen, that even small ampullary malignancies can spread along the biliopancreatic 
ducts or set of lymph node metastasis therefore being impossible to resect radically with 
either TA or EP (Yoon et al. 2005; Lee et al. 2006). Perhaps is mucosal (Tis) tumors 
possible to resect or even T1 tumors if the lesions are of the intestinal subtype, without 
signs of lymphovascular invasion (Woo et al. 2009; Alvarez-Sanchez et al. 2017). The 
trouble is to be sure that the lesion is Tis ahead of EP, and that no part of the lesion has any 
lymphovascular invasion. In a small prospective case series on patients treated with EP, that 
had an adenocarcinoma smaller than 2 cm. The study showed that 57% of patients that were 
considered not fit for surgery or that did not accept surgery could be cured with endoscopic 
resection (Petrone et al. 2013). This result, of course, must be compared with the expected 
5-year survival for stage Ia ampullary adenocarcinoma of at least 80% after surgery (Stiles
et al. 2018).
EUS, or better IDUS, have been shown to have a high accuracy in determining the T-stage
of ampullary lesions, in expert settings. The best use of EUS is to determine if a lesion is
invasive or not, in patients where endoscopic biopsies have not confirmed malignancy.
Unfortunately, are EUS dependent, to a high degree, on the endoscopists that performs the
examinations, and most published results are from expert centers. How the high
performance of EUS will stand in everyday clinical praxis is difficult to know.
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5.4.2 How to avoid “unnecessary” surgery? 
The preoperative diagnostic evaluation of lesions in the periampullary region is not easy. In 
paper IV are the frequency of surgical resections with a non-neoplastic lesion as final 
diagnosis high. The difficulties in evaluating an early malignancy, can sometimes lead to 
that surgical resections are performed on benign lesions, due to the overlap in symptoms 
and diagnostic findings (Birnbaum et al. 2017). In a consensus statement from the 
International Study group of Pancreatic Cancer Surgery it is stated that in 5-13% of the 
patients resected with pancreatoduodenectomy for presumed periampullary cancer is the 
final diagnosis benign. On the other hand, 5-9% of the patients operated because of chronic 
pancreatitis have an undiscovered malignancy (Asbun et al. 2014). In the consensus 
statement, it was concluded that no tissue diagnosis was needed before surgery in cases 
where a solid mass, suspicious for malignancy, can be seen on MDCT. However, the 
consensus statement does not include any discussion about the indications for PDE among 
patients with ampullary adenocarcinoma. Perhaps has the knowledge that pancreatic cancer 
does not need any histological confirmation prior to surgery influenced the treatment 
decisions concerning patients with ampullary cancer. In paper IV, 38% of the patients that 
went straight to surgery without any preoperative efforts to get an endoscopic biopsy had a 
non-neoplastic final diagnosis (see section 4.4.7.2.).  
5.4.3 Suggested evaluation algorithm for suspected ampullary lesions  
To avoid unnecessary surgical resections on patients with suspected ampullary neoplastic 
lesions should all patients without obvious invasive signs on MDCT undergo endoscopic 
evaluation with duodenoscopy, for visual examination, and biopsies, see Figure 21 Patients 
with confirmed malignancy, that are capable of handling major surgery should not undergo 
EP and take the risk of complications prior to curative resection. This because of the 
difficulties to make certain that the lesion is only a Tis tumor and that it has no lymph node 
involvement prior to resection. Among elderly patients and those not fit for major surgery 
can EP be a curative possibility if they have a small adenocarcinoma (<2cm) (Petrone et al. 
2013).  
If biopsies reveal adenoma regardless of grading of dysplasia there is a need for further 
investigations with MRI, or EUS if the right expert is available. Small adenomas (<2cm) 
might be resected with EP without further investigations or even without biopsies if there 
are no malignant signs, the patient is not jaundiced (Kandler and Neuhaus 2018), and that 
the endoscopist has the proper experience of EP. If MRI or EUS cannot find any signs of 
invasive lesion in the patient with adenoma, they should be considered for an EP with a 
curative intent.  
After the EP there is a risk that an undiagnosed adenocarcinoma is revealed. The patient 
should then be referred for curative surgical resection or palliative endoscopic treatment. 
Patients with intra-ductal extension, but no proven adenocarcinoma, should be evaluated for 
surgical resection or intra-ductal radio-frequency ablation within a structured, prospective 
study protocol. 
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Figure 21. Suggested investigational algorithm for suspected ampullary neoplastic lesion 
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6 CONCLUSIONS 
The present studies present data to support the following conclusions: 
I. The proposed endoscopic classification of the endoscopic appearance of the papilla
of Vater has shown substantial inter- and intraobserver agreement for the four
different papilla types among both beginners as well as experienced endoscopists,
making it useful in further studies regarding issues concerning cannulation and
clinical management.
II. The macroscopic appearance of the papilla of Vater influences bile duct cannulation
during ERCP, were Type 2, Small papillae and Type 3, Protruding or Pendulous
papillae are more frequently difficult to cannulate than Type 1, Regular papilla.
o The frequency of difficult cannulation decreases with higher degrees of
experience.
o The frequency of failed cannulation rises if a fellow endoscopist starts
cannulation attempts, even though a more senior endoscopist takes over
cannulation after 5 minutes.
Taken together these findings need to be considered in ERCP teaching and when 
comparing cannulation studies.  
III. Endoscopic papillectomy is an important treatment option in evaluating and
curatively resecting adenomatous neoplastic lesions in the papilla of Vater.
The use of KRAS analysis of EP tissue samples needs further investigation.
IV. Preinterventional evaluation of early ampullary neoplastic lesions is difficult and
complex. If no obvious, invasive malignancy is seen on imaging, in order to avoid
uneccessary major pancreatic resections:
o patients with a suspicious ampullary neoplastic lesion should undergo
endoscopic examination done with duodenoscopy and tissue samples prior
to deciding the definitive treatment strategy.
o If biopsies show ampullary adenoma, regardless of the grading of dysplasia,
patients, ought to be considered for endoscopic papillectomy.
o Patients where tissue samples show adenocarcinoma should be sent for
surgical resection, not to delay definitive treatment or to risk leaving lymph
node metastasis behind
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7 PROPOSALS FOR FURTHER RESEARCH 
• At what level of difficult cannulation is an endoscopist considered proficient?
Evaluate the definition of DC in an educational setting. Follow trainees and evaluate
the development of the frequency of DC during their training, comparing with a
group of expert endoscopists as a reference.
• What auxiliary cannulation techniques are the most appropriate for the different
types of papillae? Probably needs to be within a Nation-wide registry to be possible
to evaluate.
• Is the endoscopic appearance of the papillae per se, an independent risk factor for
PEP irrespective of cannulation difficulties? Is there an equal risk for PEP at the
same frequency of difficult cannulation amog the different papilla types?
• Is cannulation failure more frequent if a fellow endoscopists starts cannulation
attempts? Might be possible to answer with a registry-based trial, where the
participation of the fellow is defined to make comparisons possible.
• A large multi-center (registry based again) study evaluating the diagnostic accurracy
of EUS outside of expert centres.
• A randomized controlled study on the outcome of treatment of intra-ductal
extension of adenoma. Radio-frequency ablation compared with PDE. A difficult
study that has to be done over a multitude of centers and also carefully considering
the ethical aspects.
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
För precis 300 år sedan, år 1720, presenterade Abraham Vater sin avhandling vid 
Universitetet i Wittenberg rörande gallgångens anatomi, med betoning på den allra sista 
delen innan gallgången mynnar till tolvfingertarmen. Han beskriver det vidgade parti som 
oftast finns efter att gallgång och bukspottskörtelgången smält ihop till en gemensam 
utförsgång precis innanför mynningen till tarmen. Denna del bär hans namn sedan dess, 
ampulla vaterii eller Vater´s ampull. Ampulla är ett antikt förvaringskärl tillverkat för att 
förvara olika vätskor, oftast med ett handtag på vardera sida. Vid passagen till 
tolvfingertarmen befinner sig ampulla vaterii omsluten av en knopp-liknande bildning som 
syns från insidan av tarmenoch som, till olika grad, buktar ut i tarmen. Denna bildning eller 
knopp kallad för Papilla vaterii, ”the papilla of Vater” eller ”papillen” som man säger i 
”branschen”. Papillen beskrevs inte av Abraham Vater men bär ändå hans namn av lite 
oklar anledning.  
Gallgången och bukspottskörtelsgången mynnar vid denna gemensamma öppning till 
tolvfingertarmen. Dessa gångsystem ska hantera, dels alla leverns utsöndringar, så kallad 
galla, samt alla de olika kraftfulla matspjälkningsenzym, nödvändiga för näringsupptaget, 
som utsöndras i bukspottet. Dessa, två av de viktigaste vätskorna för att magtarmkanalen, 
och därmed kroppen, ska kunna sköta sina funktioner samlade i en mynning. Galla 
innehåller även olika ämnen som levern renat blodet ifrån och som kroppen behöver göra 
sig av med. Det för med sig att hinder i gallgången leder snabbt till mycket allvarliga 
sjukdomstillstånd.  
Det finns flera olika sjukdomstillstånd som kan orsaka hinder i utflödet av galla eller 
bukspott. Det vanligaste är gallstenar, men även olika tumörsjukdomar eller kroniska 
inflammationer kan också orsaka hinder i gallflödet. Det tydligaste symtomet på hinder i 
gallflödet är, gulsot, även kallat ikterus. Det finns många olika anledningar till ikterus men 
bland de vanligare är hinder i gallvägarna.  
Genom åren har olika tekniker utvecklats för att diagnosticera och åtgärda hinder i 
gallvägarna. Från början handlade det mest om olika kirurgiska operationer, men med tiden 
har titthålsteknik eller endoskopiska tekniker tagit över mer och mer.  
Endoskopi är ett samlingsbegrepp för olika metoder för att med böjliga och styrbara 
slanglika instrument ta sig in genom olika kroppsöppningar och med en kamera i toppen av 
instrumenten undersöka eller åtgärda olika tillstånd inuti kroppen, exempelvis i 
magtarmkanalen. En vanlig sådan är endoskopiskt instrument är ett gastroskop. 
Sedan den första endoskopiska undersökningen av gallgången, 1968, har den endoskopiska 
tekniken utvecklats till att bli en helt egen disciplin inom medicinen med fler och fler 
användningsområden.  
Endoskopisk retrograd kolangiopankreatografi, förkortat ERCP, kallas den endoskopiska 
teknik som kan diagnosticera men framförallt behandla sjukdomstillstånd i gallgång och 
bukspottskörtelsgång. ERCP går till så att man med hjälp av ett specialendoskop, med 
kamera som ser åt sidan, tar sig förbi magsäcken, ut i tolvfingertarmen ned till i nivå med 
papillen. Väl på plats vid papillen är nästa steg att försöka föra in olika katetrar med ledare 
in i den gång man vill behandla, vilket vanligen är gallgången. Att få in katetrarna i rätt 
gång, så kallad kanylering, kan vara en tekniskt svår manöver, men samtidigt helt 
nödvändig för att kunna genomföra ERCPn. Manipulationen av papillen och den 
gemensamma öppningen för gallgång och bukspottskörtelsgång i samband med ERCP är 
inte riskfritt. Bukspottskörteln är ett lättretat organ som innehåller kraftfulla enzymen och 
det finns en risk att man startar en bukspottskörtelsinflammation, en pankreatit, i samband 
med ERCPn. Pankreatiter är, i detta sammanhang, oftast lindrigt och kräver några dagars 
extra sjukhusvård, men kan i enstaka fall bli mycket svår och till och med ha dödlig utgång. 
Det är känt sedan länge att svårigheter vid kanylering av papillen, såsom lång 
kanyleringstid, många manipulationer med katetrarna på papillen (attempts) och att man 
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kommer in i bukspottskörtelsgången av misstag med ledare eller kateter, ökar risken för 
akut bukspottskörtelinflammation, post-ERCP pankreatit (PEP).  
I denna avhandling utreds två olika aspekter av förhållanden centrerade kring papilla 
vaterii. De första två delarbetena handlar om hur det varierande utseendet hos papilla vaterii 
skulle kunna påverka hur svårt det är att genomföra kanylering vid ERCP.  
För att sedan i de två sista delarbetena, dels utvärdera endoskopisk operation av tumörer i 
papilla vaterii; tumörer som kan vara förstadier till cancer. För att till sist utvärdera den 
komplicerade utredningen som föregår beslut om antingen kirurgisk operation eller 
endoskopisk operation av både förstadier till cancer och små cancertumörer utgående från 
”papillen”. 
Utseendet av papillen och gallgångskanylering 
Sedan man startade med ERCP i slutet av 1960-talet har det varit diskussion kring hur man 
ska göra för att kanylera gallgången på bästa vis för att, om möjligt, undvika att patienten 
får pankreatit. Mängder med olika aspekter har belyst, samt både medicinska och tekniska 
åtgärder testats med varierande framgång. I beskrivningar av ERCP teknik framhålls ofta 
att utseendet hos själva papillen, den knopp där gången mynnar, har betydelse för hur svårt 
det kan vara att kanylera. Det finns dock ingen som har mätt hur svårt, eller ens om det 
stämmer att det är svårare att kanylera. Det finns heller inte någon standard eller 
överenskommelse för hur papillen utseende varierar och vilka olika typer av utseende som 
man kan tänkas vara intressanta.  
För att utreda frågan om hur papillens utseende påverkar svårigheter vid 
gallgångskanylering behövs flera olika pusselbitar. Först behöver man avgöra vad som är 
att betrakta en svår kanylering, sedan måste man skapa ett ramverk, en klassifikation, för 
vilka utseenden av papillen som är aktuella. När dessa båda delar är på plats, kan man börja 
mäta hur kanyleringen fungerar när man som undersökare ställs inför en papill av en 
speciell typ, med ett speciellt utseende.  
Genom ett nordiskt forskningssamarbete inom den skandinaviska endoskopiföreningen 
(SADE), skapades, 2014, en definition för ”svår kanylering” (difficult cannulation) av 
gallgången. Resultatet av studien blev, att definitionen för svår kanylering uppfylls om 
något av dessa tre kriterier uppfylls, om man försöker komma in gallgången i mer än 5 
minuter, manipulerar papillen med katetrar mer än 5 gånger (attempts) eller hamnar med 
ledare eller kateter i bukspottskörtelsgången mer än 1 gång.  
Nästa steg för att besvara frågan om utseendet av papillen påverkar svårigheter vid 
gallgångskanylering, var att skapa en klassifikation av det endoskopiska utseendet av 
papillen, som är det första delarbetet i denna avhandling. Viktigt i samband med skapandet 
av klassifikationer som bygger på olika bedömares åsikter, är att de olika bedömarna är 
rimligt överens om hur de bedömer det hela. I den första studien skapades först en 
klassifikation bestående av fyra olika typer av papillutseenden. Vanlig papill, Typ 1, Liten 
papill, Typ 2, Utbuktande eller nedhängande papill, typ 3 samt Veckad eller fårad papill, 
typ 4. Dessa skapades utifrån, dels analys av flertalet fotografier av papiller, men även 
utifrån erfarenhet hos experter inom ERCP.  
För att mäta hur väl olika endoskopister, både experter och nybörjare, var överens om 
vilken typ av papill de såg och kunna avgöra till vilken av de olika typerna som papillen 
tillhörde, skapades en internetbaserad enkät. I enkäten var det 50 olika papiller, tillhörande 
de fyra olika fördefinierade typerna, avbildade med fotografier. Enkäten besvarades av 18 
olika endoskopister från hela Norden, för att värdera att de var rimligt överens. För att se att 
de även var överens med sig själva fick det besvara enkäten ytterligare en gång efter 3 
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månader. Resultatet genomgick statistisk analys och det visade på ”ansenlig” 
överenskommelse både mot den föreslagna klassifikationen och att endoskopisterna svarade 
liknande bägge gånger. Därmed var den föreslagna klassifikationen färdig att tas i bruk.  
För att mäta i vilken omfattning som det blev ”svår kanylering” för de olika typerna av 
papillutseende planerades en studie med deltagande kliniker från hela Norden. Studien gick 
ut på att mäta gallgångskanyleringen (tiden för kanylering, antal försök, och om kateterna 
kom in i bukspottskörtelgången) samt att i samband med detta avgöra vilken typ av 
papillutseende som patienten hade. Gallgångskanyleringen mättes på 1401 patienter vid 11 
olika sjukhus i Sverige, Finland och Norge. Studien visade att gallgångskanylering oftare 
blev svår om papillen är Liten eller platt (typ 2) eller Utbuktande eller nedåthängande (typ 
3) jämfört med det Vanliga papillutseendet (typ 1). Hur ofta kanyleringen blev svår berodde 
också på hur erfaren endoskopisten var, samt att om en oerfaren starta att kanylera fanns 
lite ökad risk att man misslyckades helt med kanyleringen.
Därmed kunde slutsatsen dras att det endoskopiska utseendet av papilla vaterii påverkar hur 
ofta gallgångskanyleringen blir svår.
Endoskopisk utredning och behandling av tidiga tumörer i papilla vaterii. 
En ovanlig orsak till hinder av gallvägarna är tumörer som utgår ifrån själva papillen. Innan 
det fanns endoskopi upptäcktes dessa nästan aldrig innan de blivit så stora att det inte gick 
att klargöra var de kom från, men med ökande användning av endoskopi och förbättrad 
röntgendiagnostik har gjort att det upptäcks små tumörer, och även förstadier till cancer, i 
papillen. Om det redan är cancer opereras patienterna med en stor operation där halva 
bukspottskörteln, gallgången och gallblåsa, hela tolvfingertarmen och del av magsäcken tas 
bort. För att undvika det, har en endoskopisk metod att ta bort förstadier till cancer, så 
kallade adenom, papilladenom, utvecklats.  
I den tredje studien i denna avhandling, utvärderas resultaten av endoskopisk operation 
(endoskopisk papillektomi, EP) av papilladenom under nästan en 10 års period. Då adenom 
i papillen är ovanligt, handlar det om få patienter som är aktuella för behandling. I studien 
inkluderades 36 patienter som genomgick EP för att bli botad från förmodat eller verifierat 
adenom. EP går till så att man i samband med ERCP, med hjälp av en metalsnara, bränner 
av själva papillen med tillhörande adenom.  
Resultaten från studien visar att metoden är relativt säker, med något fler komplikationer än 
vid vanlig ERCP, samt att i minst 50% av patienterna kan man undvika stor kirurgisk 
operation och att de botas med ingreppet. Bland de som inte botas bidrar EP med att 
säkerställa diagnos på tumören innan operation, då vanliga, små vävnadsprover visade sig 
ha mycket svårt att avgöra om adenomet redan blivit en cancer. Det visade sig också att 
flera av de fall som man tolkade som ”snälla” adenom innehöll cancer även om 
vävnadsprover inför den endoskopiska operationen inte kunde visa på det.  
För att gå vidare med den frågan beslutade vi att undersöka samtliga som genomgått både 
endoskopisk operation (EP) samt den klassiska kirurgiska operationen på grund av tumör i 
papillen under åren 2006–2018. Det var för att bedöma dels hur utredningen av dessa lite 
ovanliga patienter gått till samt om man kunde dra några lärdomar utifrån det.  
Efter en del letande kunde till sist alla 172 patienter identifieras som kirurgiskt eller 
endoskopiskt opererats på grund av tumör i papillen där man inte redan såg en stor tumör på 
röntgen.  
Efter att alla journaler och undersökningssvar var genomgångna kunde man identifiera ett 
par problem som man behöver ta hänsyn till vid utredning av dessa patienter. Det fanns en 
grupp av patienter som opererades med kirurgisk operation utan att man hade tagit 
vävnadsprov inför operationen, trots att man inte var helt säker på att det fanns en tumör på 
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röntgen. Hälften av patienterna hade trots det en cancer men i nästan hälften visade sig att 
blivit opererade i onödan.  
Det fanns även en grupp patienter som gick till kirurgisk operation där vävnadsprover i 
samband med endoskopisk undersökning visade adenom, ett förstadium till cancer, men 
ingen säker cancer. Även bland dessa hade cirka hälften cancer efter operationen medans 
resterande fortsatt hade adenom. De med adenom kunde möjligen ha botats med en 
endoskopisk operation istället. Av dessa kan man inte säga att de opererades i onödan utan 
möjligen att de opererades för mycket, men det kan man inte veta säkert i efterhand.  
De patienter som opererats där vävnadsprover visat cancer innan hade 44 av 45 cancer. Den 
sista patienten hade ett stort adenom, förstadium till cancer.   
I studien fanns också 76 patienter som opererats med endoskopisk operation, på samma vis 
som i den förra studien, och utav dessa blev över hälften botade från adenom med hjälp av 
den endoskopiska operationen. De som inte botades fick en säkerställd diagnos och de som 
visade sig ha cancer kunde senare opereras men vetskap om att det var rätt att operera dem.  
Slutsatserna blev att om man misstänker en tumör i papillen bör man försöka ta 
vävnadsprover innan man beslutar om operation. Visar vävnadsproverna förstadier till 
cancer, adenom, bör man fundera på om inte försök med endoskopisk operation är det bästa 
för patienten. Visar vävnadsproverna cancer ska patienten genomgå kirurgisk operation.   
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